

VOLUME **1**

GH PRO EPO IL2 IL3 IL4 IL5 IL6 IL7 IL9 IL11 IL12
IL23 IL12RA IL27 IL13 IL15 IL21 IL16 IL17 IL25 GM

GCSF IFN α IFN β IFN ω IL28A

IL28B IL29 IFN γ IL10 IL19 IL20

IL22 IL24 IL26 IL1F IL1F10

IL1RA IL18 FGF HGF TLR

LT α LT β TNF TRAIL RANK L

FasL Fas HMGB1 MCSF

The Cytokine Handbook

FOURTH EDITION

EDITED BY

Angus W Thomson

Michael T Lotze



EGF Flt3L SCF VEGF MIF IL8 CXC C-C TGF β BMP

The Cytokine Handbook

Fourth edition

VOLUME I

This Page Intentionally Left Blank

The Cytokine Handbook

Fourth edition

VOLUME I

Edited by

Angus W. Thomson

Starzl Transplantation Institute

University of Pittsburgh School of Medicine, USA

Michael T. Lotze

Molecular Medicine Institute

University of Pittsburgh School of Medicine, USA



ACADEMIC PRESS

An imprint of Elsevier Science

Amsterdam • Boston • London • New York • Oxford • Paris
San Diego • San Francisco • Singapore • Sydney • Tokyo

This book is printed on acid-free paper

Copyright © 2003 Elsevier Science Ltd
except for Chapters 5 and 8 which are a US Government work
in the public domain and not subject to copyright

First edition published 1991
Second edition published 1994
Third edition published 1998
Fourth edition published 2003

All rights reserved

No part of this publication may be reproduced or transmitted in any form or by any means,
electronic or mechanical, including photocopying, recording, or any information storage and
retrieval system, without permission in writing from the publisher

Academic Press
An Imprint of Elsevier Science
84 Theobald's Road, London WC1X 8RR, UK
<http://www.academicpress.com>

Academic Press
An Imprint of Elsevier Science
525 B Street, Suite 1900 San Diego, California 92101-4495, USA
<http://www.academicpress.com>

ISBN 1-12-689663-1

Library of Congress Catalog Number: 2002114101

British Library cataloguing in Public Data

Vol.I

1. Cytokines – Handbooks, manuals, etc. 2. Chemokines – Handbooks, manuals, etc.
 - I. Thomson, Angus W. II. Lotze, Michael T.
- 611'.0185

Typeset by J&L Composition, Filey, North Yorkshire
Printed and bound in Great Britain by The Bath Press, Avon

Contents

Preface to the First Edition	xiii
Preface to the Second Edition	xv
Preface to the Third Edition	xvii
Preface to the Fourth Edition	xix
Foreword	xxiii
<i>Joost J. Oppenheim</i>	

Volume 1

SECTION I. BASIC CYTOKINE BIOLOGY

1	The cytokines: an overview <i>Jan Vilček</i>	3
2	Cytokine genetics: Polymorphisms, functional variations and disease associations <i>Grant Gallagher, Joyce Eskdale, Jeff L. Bidwell</i>	19
3	The phylogeny of cytokines <i>Chris J. Secombes and Pete Kaiser</i>	57
4	Cytokine signaling <i>Brian E. Szente</i>	85

SECTION II. THE CYTOKINES AND CHEMOKINES

Subsection A. The Hematopoietin Family Members

5	Growth hormone <i>Lisbeth A. Welniak and William J. Murphy</i>	103
6	Prolactin <i>Hallgeir Rui and Marja T. Nevalainen</i>	115
7	Erythropoietin <i>Christoph Kasper</i>	149

8	Interleukin-2 <i>Jian-Xin Lin and Warren J. Leonard</i>	167
9	Interleukin-3 <i>John W. Schrader</i>	201
10	Interleukin-4 <i>Hideho Okada, Jacques Banchereau and Michael T. Lotze</i>	227
11	Interleukin-5 <i>Chee Choy Kok, Gretchen T. Schwenger, Ron I.W. Osmond, Debra L. Urwin and Colin J. Sanderson</i>	263
12	Interleukin-6 Family <i>Tadamitsu Kishimoto</i>	281
13	Interleukin-7 <i>Peter K.E. Trinder, Markus J. Maeurer</i>	305
14	Interleukin-9 <i>Jean-Christophe Renauld and Jacques Van Snick</i>	347
15	Interleukin-11 <i>James C. Keith, Jr.</i>	363
16	Interleukin-12 Family: [IL-12, 23, 12RA and 27] <i>Pawel Kalinski, Walter J. Storkus, Angus W. Thomson, and Michael T. Lotze</i>	383
17	Interleukin-13 <i>Gabriele Grünig, Jan E. de Vries and Rene de Waal Malefyt</i>	409
18	Interleukin-15 and 21 <i>Michael R. Shurin, Irina L. Tourkova, Holger Hackstein and Galina V. Shurin</i>	431
19	Interleukin-16 <i>Kevin C. Wilson, David M. Center, William W. Cruikshank</i>	465
20	Interleukin-17 Family [IL-17, IL-25] <i>Mary A. Antonysamy and Muneo Numasaki</i>	475
21	Granulocyte-macrophage colony-stimulating factor <i>Thomas Enzler and Glenn Dranoff</i>	503
22	Granulocyte colony-stimulating factor <i>Scott M. White and David J. Twardy</i>	525
Subsection B. The Interferon Family Members		
23	Type I interferons [IFN α , β , δ , κ , ω , τ , IL-28A (IFN λ 2) IL-28B (IFN λ 3) and IL-29 (IFN λ 1)] <i>Jeanne M. Soos and Brian E. Szente</i>	549
24	Interferon- γ <i>Gregory H. Schreiber and Robert D. Schreiber</i>	567
25	Interleukin-10 <i>YaoZhong Ding, Shuang Fu, Dmitriy Zamarin, Jonathan Bromberg</i>	603
26	The IL-10 Family [Interleukins -19, -20, -22, -24 and -26] <i>Holger Hackstein, Grant Gallagher, Sergei Kotenko, and Angus W. Thomson</i>	627
Index		xxix

Volume II

Subsection C. The Beta Trefoil Cytokines and Proinflammatory Signaling Receptors

- 27 Interleukin-1 Family [IL-1F1, F2]
Charles A. Dinarello
- 28 Interleukin-1 receptor antagonist [IL-1F3]
William P. Arend and Christopher H. Evans
- 29 Interleukin-18 [IL-1F4]
Haruki Okamura, Michael T. Lotze, Hiroko Tsutsui, Shin-ichiro Kashiwamura, Haruyasu Ueda, Tomohiro Yoshimoto and Kenji Nakanishi
- 30 Interleukin-1 Family [F5 to F10]
Sanjay Kumar
- 31 The fibroblast growth factors
Barbara Ensoli, Cecilia Sgadari, Giovanni Barillari and Paolo Monini
- 32 Hepatocyte growth factor and its receptor, MET
Wendy M. Mars, Youhua Liu and Satdarshan P. Singh Monga
- 33 Toll-like receptors
Bruce Beutler

Subsection D. The TNF Family, Receptors, and Related Molecules

- 34 Lymphotoxins
Steve W. Granger and Carl F. Ware
- 35 Tumor necrosis factor
Haichao Wang, Christopher J. Czura and Kevin J. Tracey
- 36 TRAIL/Apo2L
David H. Lynch and Avi Ashkenazi
- 37 RANKL (Receptor activator of NF κ B ligand)
Simon Blake and Ian James
- 38 CD95L/FasL and its receptor CD95 (APO-1/Fas)
Marcus E. Peter, Bryan C. Barnhart and Alicia Algeciras-Schimmich
- 39 HMGB-1
Haichao Wang, Christopher Czura and Kevin J. Tracey

Subsection E. The Tyrosine Kinase Receptor Signaling Molecules

- 40 Macrophage Colony Stimulating Factor [CSF-1]
Michael T. Lotze and John A. Hamilton
- 41 EGF family ligands
David C. Lee, C. Leann Hinkle, Leslie F. Jackson, Shunqiang Li, and Susan Wohler Sunnarborg
- 42 FLT3 ligands
Stewart D. Lyman and Hilary J. McKenna
- 43 Stem cell factor
Ian K. McNiece and Robert A. Briddell
- 44 Vascular endothelial growth factor
Dmitry I. Gabilovich and Mikhail M. Dikov

Subsection F. The Chemokines and other Cell Migration Regulating Factors

- 45 Macrophage migration inhibitory factor (MIF)
Douglas A. Arenberg, and Richard Bucala
- 46 Interleukin-8 and other CXC chemokines
Naofumi Mukaida, Sergey A. Ketlinsky, and Kouji Matsushima
- 47 CC chemokines
Alberto Mantovani, Massimo Locati, and Silvano Sozzani
- 48 Fractalkine
Violetta Zujovic and Jeffrey K. Harrison

Subsection G. The TGF Beta Family Members

- 49 Transforming growth factor β
Philip H. Howe
- 50 Inhibin/activin family
David J. Phillips
- 51 Bone morphogenic proteins
A. Hari Reddi

SECTION III. CLINICAL APPLICATION OF CYTOKINES AND CYTOKINE INHIBITION

- 52 Autoimmunity and cytokines: pathogenesis and therapy
Evangelos Th. Andreacos and Marc Feldmann
- 53 Cytokines and cancer
Megan A. Cooper and Michael A. Caligiuri
- 54 Interferon α : biology, pharmacology, and therapy for chronic viral hepatitis
Geoffrey M. Dusheiko
- 55 Haemopoietic cytokines
John L. Lewis and Myrtle Y. Gordon
- 56 Antiangiogenesis and proangiogenic
Andrew L. Feldman, Steven K. Libutti
- 57 Cytokines and transplantation
Geetha Chalasani, Fadi G. Lakkis
- 58 Cytokines and asthma
Timothy B. Oriss and Anuradha Ray
- 59 Cytokine gene transfer
Paul D. Robbins, Walter J. Storkus, and Andrea Gambotto
- 60 Antisense therapy
Stanley T. Crooke
- 61 Assays for cytokines
Theresa L. Whiteside

Index

Dedications

For Robyn, Andrew, Natalie and Emma

Angus Thomson

For Joan, Thomas, Anna, Mac and Jenny

Michael Lotze

This Page Intentionally Left Blank



Editorial Meeting, Stockholm/International Immunology Congress, July 2001.
Drs. Lotze (left), Read (center), and Thomson (right).

Preface to the First Edition

Cytokines feature at the forefront of biomedical research. An understanding of their properties is now essential for the immunology student, researcher and teacher and for today's medical practitioner who needs to understand immunologic disease and immunological approaches to therapy. The pace with which this ever-expanding field has developed has been rapid enough to exceed the most optimistic expectations and to bewilder the most assiduous student. Cytokine research is expected to provide the key to pharmacological manipulation of the immune response and commands the attention of a massive and highly focused biotechnology industry. The chapters in this book are a good representation of the areas to which molecular biology has been most successfully applied. Biotechnology companies provide most of the pure, well-characterized cell growth regulatory and effector molecules used in academic and industrial laboratories or in clinical medicine as diagnostic tools or therapeutic agents.

Cytokines represent a sought-after symposium theme in immunology, molecular biology and molecular genetics. The cytokine literature ranges from the most basic to the applied. Unfortunately, technical advances, rapid expansion and diversification have prompted narrower specialization and reduced the ease of communication. The aim of this book is to inform and to provide detailed information and reference material on the many aspects of pure and applied cytokine science. These include the molecular characteristics of cytokines, their genes and receptors, the cellular sources and targets of cytokines, their biological activities and as best can presently be defined, their mechanisms of action. Confronted with such a vast amount of new information, up-to-date coverage is an almost unattainable goal. The scope of cytokine research could only be effectively covered in a multi-authored volume and it is indeed fortunate that each chapter is written by a leading authority(ies). Although many chapters focus on individual cytokines, it is also apparent that aspects such as cell sources, molecular structure, purification and bioassay have many features in common. A certain amount of duplication is, therefore, inevitable. The cytokine network, cytokine interactions, the roles of cytokines in disease pathogenesis and the therapeutic applications of cytokine research are dealt with in detail. In attempting to provide comprehensive coverage, a chapter on phylogeny has been included. The last chapter was commissioned to provide both perspective and a somewhat sobering view of the future.

I am indebted to the many authors around the world who have so generously devoted their knowledge, energy and time to the creation of this book. I also wish to acknowledge the support of Dr Susan King, and her staff at Academic Press in London, whose skill and energy were essential in the genesis of *The Cytokine Handbook*.

Angus W. Thomson
University of Pittsburgh

This Page Intentionally Left Blank

This Page Intentionally Left Blank

Preface to the Second Edition

In the Preface to the First Edition, it was stated that to produce a book that provided up-to-date coverage of all aspects of the cytokine field was an 'almost unattainable goal'. Since the First Edition went to press in the spring of 1991, advancement both in our knowledge and understanding of the cytokine network has been predictably rapid, fully justifying the publishers' faith in a Second Edition of *The Cytokine Handbook* within 3 years. The original chapters have been revised and updated, and, with few exceptions, this has been undertaken by the original authors. Synthesis of information in the context of the cytokine network has again been a key objective. Every effort has been made to maintain currency and it is in promptly fulfilling this goal that the contributing authors deserve great credit. 'New' cytokines have, of course, emerged and continue to 'appear'. Thus, this new edition features individual chapters on IL-9, IL-10 and IL-12, with a 'stop-press' overview of IL-13 and even newer molecules that are candidates for designation as interleukins IL-14 and IL-15.

What constitutes a new interleukin? The assignment of a new designation depends on several clearly defined criteria, recently established by a sub-committee of the nomenclature committee of the International Union of Immunological Societies (Paul *et al.*, 1992). The criteria laid down include molecular cloning and expression, a unique nucleotide and inferred amino acid sequence, and the availability of a neutralizing monoclonal antibody. Furthermore, the granting of a new interleukin designation requires that the candidate molecule be a natural product of cells of the immune system (defined loosely as lymphocytes, monocytes and other leukocytes). The new interleukin must also mediate a potentially important function in immune responses and exhibit an additional function(s) so that a simple, functional name might not be adequate. Finally, these characteristic features should have been described in a peer-reviewed publication.

This new edition incorporates separate chapters on G-CSF, M-CSF and GM-CSF, whereas in the first edition, only one chapter – on 'colony stimulating factors' – covered the properties of these molecules. A chapter is also now afforded to *TGF- β* , which exhibits both inhibitory and stimulatory effects on a variety of cell types and is a potent immunosuppressant. Another significant and substantial new chapter concerns 'chemokines'. IL-8 (the 'highest' interleukin designation afforded a separate chapter in the first edition) was the first member of the chemokine family to be identified. More recently, other low molecular weight chemotactic polypeptides have been discovered that play a key role in cell activation and chemotaxis during the inflammatory response. These include RANTES (regulated upon activation, normal *T* expressed and secreted!), macrophage chemotactic and activating factor (MCAF), macrophage inflammatory protein (MIP)-1 α and MIP-1 β . All share a conserved, four cysteine motif and can be further subclassified on the spacing of the conserved cysteine residues.

Evaluation of the clinical potential of cytokines is one of the most exciting challenges of contemporary medicine. In addition, and in contradistinction to cytokine or cytokine gene therapy, the emergence of a new class of therapeutic agents, comprising soluble cytokine receptors (e.g. soluble (s) IL-1R, sTNFR, sIFN- γ R), receptor antagonists (e.g. IL-1ra) and counter-regulatory cytokines, represents one of the most important developments in the cytokine field in recent years. Successes in the sequencing, cloning and expression of cytokine receptors has facilitated production and evaluation of their therapeutic utility in several acute and chronic cytokine-mediated diseases. This exciting and challenging development is one of the themes covered under the several chapters devoted to therapeutic aspects of cytokine biology.

The last few years have seen the advent of new approaches to interrogating the roles of cytokines *in vivo*. Thus cytokine gene 'knockout' mice and mice transgenic for cytokine gene reporter constructs are likely to provide new knowledge about the *in vivo* role(s) of cytokines, especially in experimental autoimmune disorders, cancer or infectious diseases that may be difficult to mimic satisfactorily *in vivo*. The molecular genetics of cytokines (reviewed in Chapter 2) is yet another new and exciting aspect of this key field of contemporary molecular biology and medicine that has provided the impetus for the second edition of *The Cytokine Handbook*. Those who acquire knowledge by reading this book, or who are stimulated by the implications of the recent developments described herein, owe thanks to the many experts around the world who have so generously given of their valuable time, energy and expertise. The cordial and enthusiastic support of these scientists and clinicians has been an impelling influence that would be difficult to overrate. I am indebted to my colleague Dr Mike Lotze for constructive suggestions, Ms Shelly Conklin for valuable secretarial help and to Dr Tessa Picknett and her colleagues at Academic Press in London for their resolute support and guidance in ensuring that the notion of a second edition became a tangible reality.

Angus W. Thomson

REFERENCE

Paul, W.E., Kishimoto, T., Melchers, F. *et al.* (1992). *Clin. Exp. Immunol.* **88**: 367.

Preface to the Third Edition

As the Third Edition goes to press, the stream of cytokine discovery flows unabated. We are confronted by description after description of novel cytokine-controlled systems of cell differentiation and proliferation and of the role of cytokines in immune regulation. In order to keep pace with these developments, this new edition of *The Cytokine Handbook* has been completely revised and updated. The contributors are largely the same body of devoted international authorities, with several notable new additions. Amongst the newcomers to the extensive panoply of cytokines covered in this edition are the recently designated interleukins (IL)-16 (formerly lymphocyte chemotactic factor), IL-17 (identified originally as cytotoxic T lymphocyte antigen-8) and IL-18 (interferon- γ inducing factor). The daunting expansion of new information is perhaps better illustrated by the 'explosion' of chemokines. About sixty distinct human chemokine gene products have been identified to date. Regarded historically as regulators of leukocyte trafficking, chemokines have recently made a major impact in the area of infectious disease, including dramatic new understanding that chemokine receptors are at the center of HIV pathogenesis. Just two examples of chemokines that have recently come to prominence are eotaxin (the CCR-3 receptor-specific, eosinophil-selective chemokine) and the structurally unique fractalkine, with intrinsic adhesion and chemotactic activities. Two chapters are now devoted to the vastly expanding area of chemokines and their receptors.

The Third Edition sees individual chapters afforded to IL-1 through IL-15, with the exception of IL-14, reflecting the current uncertainty about the identity of the IL-14 molecule. The TNF-related cytokine-receptor superfamily of secreted and membrane-bound ligands that includes TNF/lymphotoxin (α/β , CD40, Fas and 4-1BB systems, now appears to have important functional roles in the immune response. Each member is paired with a specific cell surface receptor(s) that, together, form a corresponding family of receptors. Recent studies have revealed important and unique roles of the TNF-related ligands and receptors that are covered in an additional new chapter.

In addition to coverage of the colony-stimulating factors G-, M- and GM-CSF, two new chapters in this edition are afforded to individual hematopoietic cytokines – stem cell factor (SCF) (c-kit ligand) and flt-3 ligand – that have many biological functions in common. SCF is a potent costimulatory or synergistic factor in cytokine cocktails for manipulation of hematopoietic cells. It appears to be of value in the combination of *ex vivo* 'expansion' technologies with gene transfer methods for the correction of genetic disease or the support of multiple chemotherapy cancer patients. The recently cloned cytokine flt-3 ligand has been shown to dramatically increase the numbers of functional dendritic cells and also to increase natural killer cells *in vivo*. Moreover it exerts anti-tumor activity, raising expectation of a future role of this molecule as a human immunotherapeutic agent.

Therapeutic applications of cytokines are now covered in detail in several chapters, including a new chapter on cytokine gene therapy. The first therapeutic cytokine gene transfer study began several years ago in patients with advanced malignancy; now numerous trials have been approved for the transfer of cytokine genes to tumor cells, tumor-infiltrating lymphocytes, blood lymphocytes, or fibroblasts. A few studies involve the use of cytokine genes for the treatment of non-malignant conditions, such as rheumatoid arthritis. A new chapter in this edition reviews progress in cytokine gene therapy.

As in the two previous editions, valuable up-to-date practical information is included in the extensive account of cytokine assays. The phylogeny of cytokines has become such a growth area that the information can barely be contained in a single chapter.

I am again immensely indebted to the many experts around the world who have made this new edition possible. On the home front, my colleague Dr Mike Lotze has been a constant source of creative suggestions and lively discussion. My thanks are due once again to Dr Tessa Picknett, senior editor, and also to Mr Duncan Fatz and Ms Emma White at Academic Press in London, and to Ms Shelly Conklin for invaluable secretarial assistance.

Angus W. Thomson

Preface to the Fourth Edition

It is also said that Sisyphus, being near to death, rashly wanted to test his wife's love. He ordered her to cast his unburied body into the middle of the public square. Sisyphus woke up in the underworld. And there, annoyed by an obedience so contrary to human love, he obtained from Pluto permission to return to earth in order to chastise his wife. But when he had seen again the face of this world, enjoyed water and sun, warm stones and the sea, he no longer wanted to go back to the infernal darkness. Recalls, signs of anger, warnings were of no avail. Many years more he lived facing the curve of the gulf, the sparkling sea, and the smiles of earth. A decree of the gods was necessary. Mercury came and seized the impudent man by the collar and, snatching him from his joys, led him forcibly back to the underworld, where his rock was ready for him.

The Myth of Sisyphus, Albert Camus; 1940.

Camus was awarded the Nobel Prize for Literature in 1957 for his existentialist contributions to finding order and meaning for man living in a world absurd and, at the time he wrote it, wracked by war. The notion of a mortal committed to daily striving to move his rock uphill serves as a suitable metaphor for cytokines, literally cell movers. At some level it also mirrors the profound labors of our contributors who, in each edition, find the energy to move their chapters a bit closer to the apogee of fuller understanding and bounded exposition. If this work is at all successful, it is because of them and their professorial stance to organizing what is becoming almost an impossibly large set of contributions to the literature.

Astute observers will find this fourth edition substantially altered, now in two volumes, organized around cytokine families, many of them revealed by the availability of new sequence data arising from the human genome project. It also introduces quotes chosen in most part by the author of each chapter and denoting some of the personal affectations of each contributor. It has striven to be complete and still readable allowing access to the considerable literature now available for many of these factors which, Mercury-like, bring and move cells to their appointed fate. The final section knits together the individual cytokines into the clinical implications and, in some instances, applications of cytokines. The hope is that some of them might find their way singly, or most often, in pairs, into useful recombinant pharmaceutical agents. Since the last edition, interleukin 1 receptor antagonist (IL-1RA) has

been approved for the therapy of rheumatoid arthritis (Schiff, 2000). The successful application of TNF antagonists in chronic inflammatory conditions continues to expand with what we suspect will be an increasing number of indications moving beyond arthritis (Criscione and St Clair, 2002) and inflammatory bowel disease to other difficult clinical problems. Up to the moment of press, we have been cognizant of new molecules and new insights and have incorporated these with assistance and support of our editor up to the recently identified IL-28 and IL-29! (Kotenko *et al.*, 2002; Sheppard *et al.*, 2002).

Some of the major advances captured in this edition beyond those made possible by the availability of the full human and mouse genome represent the increased power of new technology. These include application of quantitative polymerase chain reaction (PCR) assessment of cytokines (Walker, 1998; Gulietti *et al.*, 2001; Rajeevan *et al.*, 2001), availability of measurement of multiple cytokines in ELISpot assays (Bennouna *et al.*, 2002; Leong *et al.*, 2002; Meidenbauer *et al.*, 2002; Scheibenbogen *et al.*, 2002; Shmitz *et al.*, 2002) as well as microarrays (Benson *et al.*, 2002; Cappellen *et al.*, 2002) allowing careful evaluation of the downstream messages induced by cytokines and chemokines. The proteomic analysis and patterning of individual cytokines *in vitro* and *in vivo* is less fully developed (Petricoin *et al.*, 2002; Schweitzer *et al.*, 2002) but by the time of the fifth edition is expected to allow greater analysis of the complexity of cell communication mediated by cytokines. Also the deeper understanding of individual cells or cell mixtures has been made possible by the development of so-called high content screening using integrated high resolution fluorescence microscopy, data algorithm development and display and automation (Ghosh *et al.*, 2000; Taylor *et al.*, 2001). We anticipate that studying cells interacting with each other will provide a wealth of additional information, as yet only modestly pursued in the available literature.

We would like to dedicate this edition of *The Cytokine Handbook* to our colleagues, the scientists laboring within academe and the biotechnology/pharmaceutical industries. Like Sisyphus and his spouse, they have to work long hours, often together, to move their chosen cytokine or chemokine closer to a fuller understanding and ultimate utility in discerning the biology writ large by their production, in full display within the public square. It is our expectation that within the bounds of creating new knowledge and creating value, that application of this knowledge might improve human health and the common weal. Finally to Shelly Conklin who organized our manuscripts dutifully as they each arrived, to Bridget Colvin for her scholarly contribution to the quotes, and to Jacqueline Read who together with Tessa Picknett as our editors, made the task of developing this edition more joyful than if it were in less able hands, we offer our humble appreciation and thanks.

Michael T. Lotze
Angus W. Thomson

REFERENCES

- Bennouna, J., Hildesheim, A., Chikamatsu, K. *et al.* (2002) Application of IL-5 ELISPOT assays to quantification of antigen-specific T helper responses. *J. Immunol. Methods* **261**(1–2): 145–156.
- Benson, M., Svensson, P.A., Carlsson, B. *et al.* (2002) DNA microarrays to study gene expression in allergic airways. *Clin. Exp. Allergy* **32**(2): 301–308.
- Cappellen, D., Luong-Nguyen, N.H., Bongiovanni, S. *et al.* (2002) Transcriptional program of mouse osteoclast differentiation governed by the macrophage colony-stimulating factor and the ligand for the receptor activator of NFkB. *J. Biol. Chem.* **277**: 21971–21982.
- Criscione, L.G. and St Clair, E.W. (2002) Tumor necrosis factor-alpha antagonists for the treatment of rheumatic diseases. *Curr. Opin. Rheumatol.* **14**(3): 204–211.
- Ghosh, R.N., Chen, Y.T., DeBiasio, R. *et al.* (2000) Cell-based, high-content screen for receptor internalization, recycling and intracellular trafficking. *Biotechniques* **29**(1): 170–175.

- Gulietti, A., Overbergh, L., Valckx, D. *et al.* (2001) An overview of real-time quantitative PCR: applications to quantify cytokine gene expression. *Methods* **25**(4): 386–401.
- Kotenko, S.V., Gallagher, G., Baurin, V.V. *et al.* (2003) IFN- λ mediate antiviral protection through a distinct class II cytokine receptor complex. *Nature Immunology* **4**, 69–77.
- Leong, S.P., Peng, M., Zhou, Y.M. *et al.* (2002) Cytokine profiles of sentinel lymph nodes draining the primary melanoma. *Ann. Surg. Oncol.* **9**(1): 82–87.
- Meidenbauer, N., Gooding, W., Spitzer, L. *et al.* (2002) Recovery of zeta-chain expression and changes in spontaneous IL-10 production after PSA-based vaccines in patients with prostate cancer. *Br. J. Cancer* **86**(2): 168–178.
- Petricoin, E.F., Ardekani, A.M., Hitt, B.A. *et al.* (2002) Use of proteomic patterns in serum to identify ovarian cancer. *Lancet* **359**(9306): 572–577.
- Rajeevan, M.S., Ranamukhaarachchi, D.G., Vernon, S.D. and Unger, E.R. (2001) Use of real-time quantitative PCR to validate the results of cDNA array and differential display PCR technologies. *Methods* **25**(4): 443–451.
- Scheibenbogen, C., Sun, Y., Keilholz, U. *et al.* (2002) Identification of known and novel immunogenic T-cell epitopes from tumor antigens recognized by peripheral blood T cells from patients responding to IL-2-based treatment. *Int. J. Cancer* **98**(3): 409–414.
- Schiff, M.H. (2000) Role of interleukin 1 and interleukin 1 receptor antagonist in the mediation of rheumatoid arthritis. *Ann. Rheum. Dis.* **59**(Suppl 1): i103–i108.
- Schweitzer, B., Roberts, S., Grimwade, B. *et al.* (2002) Multiplexed protein profiling on microarrays by rolling-circle amplification. *Nat. Biotechnol.* **20**(4): 359–365.
- Sheppard, P., Kindsvogel, W., Xu, W. *et al.* (2003) IL-28, IL-29 and their class II cytokine receptor IL-29R. *Nature Immunology* **4**, 63–68.
- Shmitz, M., Rohayem, J., Paul, R. *et al.* (2002) Quantification of antigen-reactive T cells by a modified ELISPOT assay based on freshly isolated blood dendritic cells. *J. Clin. Lab. Anal.* **16**(1): 30–36.
- Taylor, D.L., Woo, E.S. and Giuliano, K.A. (2001) Real-time molecular and cellular analysis: the new frontier of drug discovery. *Curr. Opin. Biotechnol.* **12**(1): 75–81.
- Walker, K.B. (1998) Detection and analysis of cytokine mRNA in tissues and cell lines. *J. Immunol. Methods* **212**(1): 113–123.

This Page Intentionally Left Blank

Foreword to the Fourth Edition

What are cytokines?

As so aptly discussed by Jan Vilcek in the introductory chapter to this book, *The Cytokine Handbook*, cytokines are regulatory peptides that can be produced by every nucleated cell type in the body. Cytokines have pleiotropic regulatory effects on haematopoietic and many other cell types that participate in host defense and repair processes. Cytokines therefore include lymphocyte-derived factors known as 'lymphokines', monocyte-derived factors called 'monokines', haematopoietic 'colony stimulating factors', connective tissue 'growth factors', and chemotactic chemokines.

Why do cytokines exist?

The evolution of large multicellular organisms require the development of intercellular messengers such as hormones, neuropeptides and cytokines to permit marshalling of co-ordinated cellular responses. It has been proposed that the structural homology between adhesion proteins that mediate cell-contact-dependent interactions and cytokine ligands, suggests that soluble cytokines evolved from cell-associated signals (Grumet *et al.*, 1991). In fact, a number of cytokines and their receptors exist in both soluble (shed) and cell-associated form and can have different functional consequences in each state.

How are cytokines different from hormones?

Endocrine hormones, which are generally produced by specialized glands, are present in the circulation and serve to maintain homeostasis. In contrast, most cytokines usually act over short distances as autocrine or paracrine intercellular signals in local tissues and – with the exception of macrophage colony-stimulating factor (M-CSF), stem cell factor, erythropoietin and a latent form of the transforming growth factor β (TGF β) – only occasionally spill over into the circulation and initiate systemic reactions. Except for the above, cytokines generally are not produced constitutively, but are generated in response to danger signals to contend with challenges to the integrity of the host. The functions of cytokines are distinct from those of hormones, since they serve to maintain homeostasis by regulating innate host defense and the immune system, through damage control and by promotion of reparative processes.

How did lymphokines come to be discovered?

The possibility that cell-derived factors mediate biological activities was first suggested by experiments carried out by Rich and Lewis (1932). They observed that migration of neutrophils and macrophages in

cultures of tuberculin-sensitized tissues was inhibited by antigen. Waksman and Matoltsy (1958) observed that macrophages in monolayer cultures were actually stimulated rather than damaged by exposure to tuberculin antigens. George and Vaughan (1962) improved the technique of evaluating migration of mononuclear cells using capillary tubes. The study of 'lymphokines' was initiated concurrently by David *et al.* (1964) and Bloom and Bennet (1966). They used this technique to show that antigens could stimulate sensitized lymphocytes in cultures to produce macrophage migration inhibitory factors (MIF). At about the same time, supernatants of mixed leukocyte cultures were found by Kasakura and Lowenstein (1965) to be 'blastogenic' for lymphocytes. This 'blastogenic factor' (BF) was subsequently called 'lymphocyte mitogenic factor' (LMF). This was followed by the discovery of a variety of lymphocyte-derived biological activities in culture supernatants. Ruddle and Waksman as well as Kolb and Granger described a cytotoxic lymphocyte-derived mediator called 'lymphotoxin' (LT) in 1968.

In vitro monocyte migration in response to supernatants of antigen activated lymphocytes was attributed to a lymphocyte-derived chemotactic factor (LCF) (Ward *et al.*, 1969) and was correlated with the recruitment of mononuclear cells to *in vivo* inflammatory sites. MIF and the macrophage aggregation factor (MAGF) (Lolekha *et al.*, 1970) presumably served to retain cells at inflammatory sites. The necrotic centers of some granulomas could be attributed to the cytotoxic activity of LT (Kolb and Granger, 1968; Ruddle and Waksman, 1968), and the presence of lymphoblasts and frequent mitotic figures was mediated by LMF (Kasakura and Lowenstein, 1965). Moreover, identification of macrophage-activating factor (MAF) (Nathan *et al.*, 1971) and lymphocyte-derived immune interferon (IFN- γ) (Green *et al.*, 1969) provided a biological basis for acquired resistance to infectious organisms. Consequently, the various biological activities secreted by cultured antigen-stimulated lymphocytes provided *in vitro* models for the pathogenesis of *in vivo* delayed hypersensitivity reactions. These biochemically undefined, lymphocyte-derived activities were termed 'lymphokines' in 1969 by Dumonde *et al.* Discovery of the lymphokines revolutionized the conceptual basis of cell-mediated immunity and these biological activities were considered '*in vitro* correlates' of cell-mediated immunity.

What led to the recognition that lymphokines were members of the cytokine family?

In 1971–1974 Gery and coworkers showed that the lymphocyte-activating factor (LAF) was produced by adherent monocytes and macrophages (Gershon and Kondo, 1971; Gery *et al.*, 1971; Gershon *et al.*, 1974). This was the first demonstration of the existence of non-lymphocyte-derived 'monokines'. Based on this information and on his own observations that some replicating non-lymphoid cell lines, as well as virally infected non-lymphoid cells, could also produce lymphokine-like MIF and chemotactic factors, Cohen proposed that all these mediators including lymphokines should therefore be called 'cytokines' (Cohen *et al.*, 1974). This resulted in the conceptual transformation of lymphokines from subjects of interest to a minor subset of immunologists, to cytokines that function as bidirectional intercellular signals between somatic and myeloid as well as lymphoid cells, with potential impact on a great number of biological disciplines.

What developments galvanized the study of cytokines?

The development of tissue culture techniques in the 1960s enabled immunologists to detect the presence of factors in tissue culture supernatants and enabled them to perform *in vitro* studies of the mobility, proliferation, differentiation and functional capabilities of lymphocytes and other leukocytes. Cytokines are very potent and active at pM to nM concentrations. Thus, they are active at only trace levels. This makes it particularly difficult to isolate and identify the biochemical structure of these peptides. These factors, which were originally disparagingly termed 'lymphodrek', could be purified only with the development of improved chromatography and microsequencing techniques in the late 1970s. The fortuitous development of molecular biology and monoclonal antibody technologies accel-

erated the identification of cytokines in the 1980s ensuring the availability of abundant quantities of recombinant cytokines over the past decade. This has resulted in an information explosion that is reflected by *The Cytokine Handbook*.

What was the origin of the interleukin terminology?

By 1978, the confusing plethora of eponyms in existence for monocyte and lymphocyte-derived activities motivated investigators at the Second International Lymphokine Workshop – held near Interlaken, Switzerland – to propose more inclusive ‘neutral’ terms for these biological activities. The researchers recognized that the numerous monokine and lymphokine activities which they were detecting, along with a variety of bioassays, actually had numerous properties in common. This resulted in the erroneous impression that these cytokine activities, each with their own name, could all be attributable to one or two molecular entities. Paetkau proposed that monocyte-derived LAF/BAF/MCF be renamed interleukin-1 (IL-1), while lymphocyte-derived LMF/BF/TCGF should be called IL-2 (Mizel and Farrar, 1979). The interleukin terminology symbolized the broader roles of these cytokines and, with the progressive increase in the number of interleukins, now up to 27, has led to an explosive increase in the interest of investigators from a variety of disciplines in these mediators of inflammation and immunity.

Why is the cytokine nomenclature so chaotic?

Of the more than 200 cytokines that have been cloned to date, many retain their initial names, which usually denote only the functional activity that led to their discovery. Chaotic as this may be, such names are easier to recall than an interminable number of interleukins or chemokines. A minority of investigators request an interleukin designation to focus greater attention on their discovery. To qualify as an interleukin, the cytokine must be documented to have a unique amino acid sequence and functional activity involving leukocytes. The evidence is evaluated by the nomenclature and standardization committee of the International Cytokine Society and the Union of Immunological Societies who make a recommendation to the World Health Organization. Despite this rather straightforward process, committees have had to resolve conflicts concerning simultaneous claims to the IL-4 number and even a fraudulent claim (e.g. IL-4a). More recently, an error in the nucleotide sequence of the precursor region of IL-16 led to a re-evaluation of the IL-16 designation. Fortunately, the error did not involve the region of the gene coding for the mature protein and the translated amino acid sequence proved to be correct and exhibited the proposed functions of IL-16. In contrast, the nucleotide and consequent amino acid sequence of IL-14 have proven to be incorrect. Unfortunately, the correct protein sequence of IL-14, if any, remains unknown. It is therefore unclear whether IL-14 exists; hence its omission from this Handbook. Perhaps such errors can be prevented by requiring that novel cytokine sequences be independently confirmed to be eligible for an interleukin designation. Structurally distinct interleukins that use the same receptor have been given a number followed by a Greek letter, as for example IL-1 α and IL-1 β .

Is there any order to the cytokine chaos?

Despite the identification of many structurally distinct cytokines, they can be organized into groups that exhibit functional similarities based on shared receptor utilization. This holds for IL-1 α and IL-1 β as well as TNF α and LT which use shared and unshared receptors. Receptor chains are shared by a number of the cytokine groups. The IL-2 γ receptor chain is shared by IL-2, 4, 7, 9, 15 and 21. The gp130 chain of the IL-6 receptor is shared by IL-6, IL-11, LIF, oncostatin-M, CNTF and cardiotrophin-1. Members of the TNF family of ligands share receptors with homology to the TNF receptors. This includes TNF α , LT α , LT β complex, Fas ligand, CD70, CD40 ligand, CD30 ligand, nerve growth factor and more. A receptor β chain is shared by IL-3, IL-5 and GM-CSF. Homologous G-protein-coupled receptors are used by IL-8 and the chemokine family. The receptors for IFN α , β , ω , γ and IL-10 also

show homology, as do those for the TGF β family of cytokines. Since IL-12 and IL-18 have overlapping activities, their receptors also may be related. These observations permit a rational organization of cytokines into families.

The advent of additional information concerning the relationship and location of cytokine genes, shared signal transduction pathways and the tertiary structure of cytokines may enable us to further classify newly discovered cytokines. Although we have always presumed that the most important cytokines and receptors have been discovered, we are repeatedly surprised by identification not only of novel cytokines and receptors, but whole families. Undoubtedly many more cytokines will be identified now that the genome has been mapped.

Why are cytokines important?

Recombinant cytokines provide useful laboratory probes for studying the cell biology of innate and adaptive immunity and inflammation. Cytokines are the major orchestrators of host defense processes and, as such, are involved in responses to exogenous and endogenous insults, repair and restoration of homeostasis. Microbial pathogens have operated on these principles far longer than immunologists and have been shown to produce variants of proinflammatory cytokines, their receptors and chemokine antagonists that subvert and suppress the host immune and inflammatory defenses. Deletion of these products reduces the pathogenicity of these viruses. In addition to their role in host defense, cytokines appear to play a major role in development and some of them may account for as yet unidentified embryonic inductive factors. The study of cytokines is also elucidating the mechanisms underlying pathophysiological processes. Cytokines mediate not only host responses to invading organisms, tumors and trauma, but also maintain our capacity for daily survival in our germ-laden environment. In fact, the development of more sensitive methods of detection is revealing the presence of detectable, but low levels of cytokines associated with a variety of binding proteins in the serum. This probably reflects the production of cytokines in response to the many nonpathogenic stimulants present in our conventional environment. Detection of cytokines in disease states may provide useful diagnostic tools. The therapeutic administration of pharmacological doses of cytokines or at times cytokine gene therapy is being used in a wide variety of infectious diseases and in immunocompromised patients with genetic defects, AIDS, autoimmune diseases and neoplasias. This has led to the development of numerous biotechnology firms which are also evaluating antagonists of cytokines for their anti-inflammatory effects.

Why a Cytokine Handbook?

Studies of cytokines have drawn scientists from a multiplicity of fields including immunologists, hematologists, molecular biologists, neurobiologists, cell biologists, biochemists, physiologists, and others. Consequently, the burgeoning field of cytokine research is unique and interdisciplinary. The chapters in this Handbook cover the structure and functions of cytokines, their genes, receptors, mechanisms of signal transduction and clinical applications. This fourth edition of *The Cytokine Handbook* is required, at this relatively early date, to keep up with rapid developments in these dynamic disciplines. All the chapters, and even this foreword, have been updated and numerous new chapters by internationally renowned experts have been added including the new Interleukins, 19–27. The new edition has been greatly reorganized with the addition of chapters to cover the more general topics of molecular genetics, signal transduction and common structural features of cytokines and their receptors. The cytokine chapters have been grouped based on the nature of their receptors. All the hematopoietin family members including growth hormone, prolactin, erythropoietin, ciliary neurotrophic factor and nerve growth factor as well as all of the interleukins are now included. There are now separate sections with multiple chapters on the interferon family, IL-1 family, TNF family, growth factors, the chemokine family and transforming growth factor family. Finally, there is an expanded section on the therapeutic

applications of cytokines and cytokine inhibitors. Thus, this fourth edition has been considerably expanded based on progress in cytokine research and on the fact that many additional intercellular mediators should be considered cytokines and included here. Consequently, *The Cytokine Handbook* provides us with the opportunity to keep up with the rapidly evolving studies of cytokines.

Acknowledgements

I am grateful for the critical input of Drs R. Neta, M. Grimm and S. Durum and the secretarial assistance of Ms Cheryl Fogle.

Joost J. Oppenheim
Laboratory of Molecular Immunoregulation
National Cancer Institute
Maryland, USA

REFERENCES

- Bloom, B.R. and Bennet, B. (1966). Mechanism of a reaction *in vitro* associated with delayed-type hypersensitivity. *Science* **153**: 80–82.
- Cohen, S., Bigazzi, P.E. and Yoshida, T. (1974). Similarities of T cell function in cell-mediated immunity and antibody production. *Cell. Immunol.* **12**: 150–159.
- David, J.R., Al-Askari, S., Lawrence, H.S. and Thomas, L. (1964). Delayed hypersensitivity *In vitro*. *J. Immunol.* **93**: 264–273.
- Dumonde, D.C., Wolstencroft, R.A., Panayi, G.S. *et al.* (1969). Lymphokines: non-antibody mediators of cellular immunity generated by lymphocyte activation. *Nature* **224**: 38–42.
- George, M. and Vaughan, J.H. (1962). *In vitro* cell migration as a model for delayed hypersensitivity. *Proc. Soc. Exp. Biol. Med.* **111**: 514–521.
- Gershon, R.K. and Kondo, K. (1971). Infectious immunological tolerance. *Immunology* **21**: 903–914.
- Gershon, R.K., Gery, I. and Waksman, B.H. (1974). Suppressive effects of *in vivo* immunization on PHA responses *in vitro*. *J. Immunol.* **112**: 2215–221.
- Gery, I., Gershon, R.K., and Waksman, B.H. (1971). Potentiation of cultured mouse thymocyte responses by factors released by peripheral leucocytes. *J. Immunol.* **107**: 1778–1780.
- Green, J.A., Cooperland, S.R. and Kibnick, S. (1969). Immune specific induction of interferon production in cultures of human blood lymphocytes. *Science* **164**: 1415–1417.
- Grumet, M., Mauro, V., Burgoon, M.P. *et al.* (1991). Structure of a new nervous system glycoprotein, Nr-CAM, and its relationship to subgroups of neural cell adhesion molecules. *J. Cell. Biol.* **113**: 1399–1412.
- Kasakura, S. and Lowenstein, L. (1965). A factor stimulating DNA synthesis derived from the medium of leucocyte cultures. *Nature* **208**: 794–798.
- Kolb, W.P. and Granger, G.A. (1968). Lymphocyte *in vitro* cytotoxicity: Characterization of human lymphotoxin. *Proc. Natl. Acad. Sci. USA* **61**: 1250–1255.
- Lolekha, S., Dray, S. and Gotoff, S.P. (1970). Macrophage aggregation *in vitro*: A correlate of delayed hypersensitivity. *J. Immunol.* **104**: 296–304.
- Mizel, S.B. and Farrar, J.F. (1979). Revised nomenclature for antigen non-specific T cell proliferation and helper factors. *Cell. Immunol.* **48**: 433–436.
- Nathan, C.F., Karnovsky, M.L. and David, J.R. (1971). Alterations of macrophage functions by mediators from lymphocytes. *J. Exp. Med.* **133**: 1356–1376.
- Rich, A.R. and Lewis, M.R. (1932). Nature of allergy in tuberculosis as revealed by tissue culture studies. *Bull. Johns Hopkins Hosp.* **50**: 115–131.
- Ruddle, N.H. and Waksman, B.H. (1968). Cytotoxicity mediated by soluble antigen and lymphocytes in delayed hypersensitivity. *J. Exp. Med.* **128**: 1267–1279.
- Waksman, B.H. and Matoltsy, M. (1958). The effect of tuberculin on peritoneal exudate cells of sensitized guinea pigs in surviving cell culture. *J. Immunol.* **81**: 220–234.
- Ward, P.A., Remold, H.G. and David, J.R. (1969). Leukotactic factor produced by sensitized lymphocytes. *Science* **163**: 1079–1081

This Page Intentionally Left Blank

INDEX

(Note: page numbers in *italics* refer to figures and tables, those in **bold** refer to main discussions of topics. 'Plate' refers to illustrations in Plate Section)

- A-SMase, 845–6
- acromegaly, 106
- activation-induced cell death (AICD)
 - lymphocytes, 719, 890, 891,
Plate 38.1
 - multiple sclerosis, 894
- activin, 1123, **1153–69**
- angiogenesis, 1159
- anti-inflammatory actions, *1165*,
1166–7
- apoptosis, 1159–61, 1164, 1166
- binding proteins, 1155–7
- biologic activity, 1155
- branching morphogenesis, 1162–3
- cancer, 1161
- cell proliferation, 1159, 1161, 1166
- cyclin/CDK pathway, 1160
- differentiation, 1161–2
- fibrosis, 1163
- follistatin, 1159
- functions, 1158
- genes, 1154
- hematopoiesis, 1164–5
- hepatocyte growth factor, 1159,
1163
- IL-1 β , 1166–7
- IL-6 function blocking, 1166
- immune system, 1161–8
- inflammation, *1165*, 1166–7
 - clinical syndromes, 1167–8
- interactions with signaling
pathways, 1159
- lymphocytes, 1165
- MAPK pathway, 1159
- molecular characterization,
1154–5
- p53 expression, 1160
- proinflammatory actions, 1165–6
- receptors, 1157–8
 - type I, 1157
 - type II, 1157
- signaling, *1156*, 1157, *1158*
 - intracellular components,
1158–9
 - TGF β cross-regulation, 1159
- Smads, 1158–9, 1163, 1164
- TGF β synergism, 1163
- wound healing, 1163–4
- activin receptor interacting protein 1
(ARIP1), 1159
- acute phase response, IL-6, 284–5
- Ad-5, 1338
- ADAM, 970–1
- ADAM17 *see* TNF- α -converting
enzyme (TACE)
- adaptor proteins, CSF-1, 935
- ADAR family, 555, 1236, 1238
- adeno-associated virus (AAV), 1340
- adenosine deaminase, 555
 - RNA dependent (ADAR1), 555,
1236, 1238
- adenoviruses, 1338–9
- adrenal adenoma, cortisol-secreting,
661
- adrenal gland, 713
- adrenocorticotrophic hormone
(ACTH), 285, 1037
- adult respiratory distress syndrome
(ARDS)
 - CXC chemokines, 1067
 - IL-1Ra, 681
 - MIF, 1041–2
 - TNF, 848
- agranulocytosis, drug-induced, 510
- AIDS, progression to, 1376
- airway diseases
 - eosinophilia, 418, 1320
 - IL-17, 495–6
 - see also* adult respiratory distress
syndrome (ARDS); asthma
- AK-155 *see* IL-26
- alcohol abuse, IL-17, 496
- ALK1, 1122
- allergic disease
 - contact dermatitis
 - IL-1Ra, 681
 - IL-17, 497
 - IL-4 animal models, 245–6
 - IL-4Ra gene variants, 234
 - IL-5, IL-4 and IL-13 coexpression,
265
 - IL-12 therapy, 398
 - IL-15, 444
 - lung and IL-13, 417, 418
 - MI-L, 486
- allograft acceptance, 1301–5

- allograft acceptance (*continued*)
 gene transfer, 1343
- allograft rejection, 489–90, 1297
 acute, 1297–9
 human studies, 1305
 CD95L, 892
 chronic, 1299–301
 human studies, 1306
 gene expression studies, 1306
 gene polymorphism studies, 1306–7
 MIF in renal transplant, 1042
- Alzheimer's disease, IL-1Ra, 680
- amino acid, 550
- amniotic fluid, IL-1Ra, 678
- cAMP, 937
- amphibians, 57
 chemokines, 68
 FGF, 75
 IL-1, 62
 IL-2, 64
 interferons, 58
 TGF β , 74
- amphiregulin (AR), 959, 960, 967–9
 receptors, 968–9
- amphoteroicin *see* HMGB1
- Anakinra, 691–2
- ancestin, 1014
- anemia
 aplastic and GM-CSF, 511, 513
 of chronic disease (ACD), 157–8
 Flt3, 996–7
 hemolytic, 1191
- angiogenesis, 1279–90
 activin, 1159
 anti-TNF α therapy, 1199
 biology, 1280–2
 bone formation, 1179
 cancer, 1281
 cardiovascular disease, 1282
 CXC chemokine inhibition, 1063
 FGFs, 755, 757–8, 758, 761
 fracture healing, 1281
 HGF, 791
 IL-8, 1057
 IL-10, 610–11
 IL-12, 393
 IL-15, 446
 IL-18 inhibition, 721–2
 inflammatory response, 1281
 inhibitors, 1220
 endogenous, 1281, 1282, 1283, 1284, 1285, 1286–8
 synthetic, 1285, 1288–9
 ocular disease, 1282
 pathologic situations, 1280
 physiologic, 1280–1
 reproduction, 1280–1
- rheumatoid arthritis, 1282
 tissue repair, 1281
 tumor growth, 1220
 VEGFs, 1017, 1019, 1024–5
 wound healing, 1281
see also antiangiogenesis
- angiopoietin-2, 1281
- angioproliferative disease, 1066
- angiostatin, 1220, 1282, 1283, 1284, 1286
- ankylosing spondylitis, 1192
- antagonism, xxv, 12–13
- anti-CD2, 1303
- anti-CD3, 169, 170, 1303
- anti-CD20 antibody, 1226
- anti-cytokine antibodies, 1387
- anti-cytokine therapy
 autoimmune disease, 1200
 cancer, 1222–3
- anti-IL-5 antibody, 1327
- anti-IL-6 receptor antibody, 294
- anti-inflammatory therapy in
 autoimmune disease, 1200–1
- anti-TNF therapy, 852
- anti-TNF α therapy
 Crohn's disease, 1199, 1201
 mechanism of action, 1199
 methotrexate combination, 1197, 1198, 1199, 1201
 psoriasis, 1199–200
 rheumatoid arthritis, 1197, 1198, 1199, 1201, 1202, *Plate 52.6*
 spondylarthropathy, 1199
- anti-VEGF antibody, 1285, 1289–90
- antiangiogenesis, 244, 1279–91
 cancer, 1281
 gene therapy, 1290
- antiangiogenic agents, clinical trials, 1285, 1287–90
- antibodies
 anti-cytokine, 1387
 ELISA, 1382, *Plate 61.2*
 immunoassay, 1383
 immunohistochemistry, 1386, *Plate 61.4*
 TAG-labeled, 1385
- antibody-dependent T cell
 cytotoxicity, 248
- antigen-induced cell death (AICD), 886–7
- antigen presenting cells (APC)
 IFN- γ , 582–3
 IL-12, 384, 385, 386, 393
 IL-12RA, 387
 IL-15, 433
 lung, 1324
- antigens in autoimmunity, 1192
- antisense therapy, 1349–68
 drugs
 molecular mechanisms, 1350–3
 splicing inhibition, 1352–3
- antiviral activity, 551
- AP-1, 827, 839, 840
 CD95L, 887
 IL-8, 1057
- AP-2, 839
- Apo2-ligand (Apo2L), 861, 862
- apoptosis, 10, 861
 activin, 1159–61, 1164, 1166
 B cell protection by IL-4, 238
 CD95-induced, 891–2, 893
 CD95 signaling, 896, 897–8, 899, 900, *Plate 38.2*
 CD95L, 890, 892, *Plate 38.1*
 defective, 1192
 FGF regulation, 765
 hepatocytes, 865
 HIV infection, 893–4
 IFN- γ , 586
 IFN type I regulated, 556
 IL-3, 215
 IL-7 protection of DTEC, 321
 IL-7R α inhibition, 313
 IL-15 inhibition, 442
 induction, 12
 keratinocytes, 444, 445, 447
 multiple myeloma, 449
 multiple sclerosis, 895
 suppression, 215
 T cells, 447
 TGF β -mediated, 1135, 1136–40, *Plate 49.6*
 prostate epithelium, 1137–8
 thymocytes, 891
 TNF α , 1215, *Plate 53.2*
 TRAIL/Apo2L, 864, 865–6
- apoptotic activating factor-1 (Apaf-1), 1138
- N-arginine dibasic convertase (NRDc), 971
- arresten, 1286
- arthritis
 gene therapy, 693–4, 696, 698, 1343
 IL-1Ra, 679–80, 687–8, 691–2, 698
 gene therapy, 693–4, 696, 698
 IL-18, 722
see also osteoarthritis; rheumatoid arthritis
- ARTS protein, 1137
- Ask1/MKK6/p38, 889
- assays for cytokines, 1375–92
 bioassays, 1377, 1378, 1379–81
 cytokine transcript detection, 1387–8

- ELISA, 1378, 1382–3, *Plate 61.2*
 ELISPOT frequency analysis,
 1388–9, 1390, *Plate 61.6, Plate 61.7*
 enhanced chemoluminescence
 technique, 1385
 flow cytometry, 1386, 1387, 1390,
Plate 61.5
 multicolor, 1387, *Plate 61.5*
 gene arrays, 1385
 immunoassays, 1377, 1378, 1382–4
 sandwich-type, 1384
 two-site principle, 1382,
Plate 61.2
 immunohistochemistry, 1386–7,
Plate 61.4
 immunometric assay (IRMA), 1382
 intracytoplasmic cytokine (ICC)
 assays, 1390
 microplate-based, 1385
 multiplex, 1384–5
 PBMC, 1385–6, *Plate 61.3*
 pyrogen for IL-1, 1377
 quality control, 1391
 reference reagents, 1391
 RNase protection, 1387, 1388
 sample preparation, 1390–1
 secretion, 1386
 selection, 1390
in situ hybridization (ISH), 1387,
 1388
 staining for proteins, 1386–7,
Plate 61.4
 types, 1376–8
- asthma, 22, **1313–28**
 adult-onset, 1314
 atopic, 1314–24
 CC chemokines, 1087
 CXC chemokines, 1068
 cytokine-directed therapies,
 1326–7
 diagnosis, 1314
 GATA-3, 1324–5
 GM-CSF production, 510
 IFN- γ , 1318, 1322–3, 1324
 IL-1Ra, 681
 IL-2, 1317, 1323–4
 IL-3, 1314
 IL-4, 1314, 1316, 1317, 1319–20,
 1323, 1325
 animal models, 245–6
 IL-5, 1314, 1315, 1316, 1317,
 1319–20
 IL-9, 354–5, 1314, 1317, 1320–1
 IL-10, 1317, 1321–2
 IL-12, 1324, 1325
 therapy, 398
- IL-13, 417–18, 1314, 1316, 1317,
 1319–20, 1322–3
 IL-15, 444
 IL-16, 470
 IL-17, 495
 IL-18, 722, 1318, 1323–4
 incidence, 1314
 MI-L, 486
 MIF, 1041
 pathogenesis, 1314–15
 T cells, 1324–6
- astroglial cells, 527
 atherosclerosis
 CX3CL1, 1104
 inflammation, 681
 atopic disease, 22, 1376
 eczema and IL-15, 447
 IL-12 therapy, 398
see also allergic disease
- dATP, 1138
 autoantibody production prevention,
 CD95/CD95L, 891
 autoimmunity/autoimmune disease,
1189–204
 anti-cytokine therapy, 1200
 anti-inflammatory therapy, 1200–1
 anti-TNF α therapy, 1197, 1198,
 1199–200
 antigens, 1192
 CD95/CD95L, 894–5
 experimental neuritis (EAN), 495
 gene therapy, 1342–3
 HGF, 791
 HMGB1, 920
 IL-1Ra, 677, 679–80, 680, 687–8
 IL-1RI, 661
 IL-4 animal models, 245–6
 IL-5, 272–3
 IL-6, 292
 IL-10, 605, 609
 gene therapy, 1342, 1343
 IL-13, 418–19
 IL-15, 447–9, 451
 IL-17, 491–5
 IL-18, 722
 initiation, 1191, 1193
 lymphoproliferative disorders, 861
 MHC, 1189–90, 1192
 models, 1192–3
 perpetuation, 1191, 1193
 prolactin, 136
 sex hormones, 1190
 stages, 1191, 1193
 susceptibility, 851–2, 1190
 T cells, 1191, 1192
 tissue damage, 1190–1, 1193
 TNE, 851–2
- B-cell malignancies
 chronic lymphocytic leukemia, 324
 IL-6, 1222
 IL-10, 1217–19
 lymphoma, 323–4
 IL-2, 170
- B cells, 4
 apoptosis protection by IL-4, 238
 CD40-dependent activation,
 239–40
 CD95, 891
 differentiation, 239–40, 314
 IL-7 role, 315, 316
 fate, 314
 Flt3, 996
 GH effects, 107, 108
 IFN- γ , 585
 IL-1 family, 647
 IL-2, 171, 185
 IL-3, 203, 204, 205–6
 IL-4, 230
 biologic effects, 237–40
 signaling, 235
 IL-5 activity, 272–3
 IL-6, 273, 282
 IL-7, 314–18
 IL-7R, 314
 IL-9, 349
 IL-12, 392–3
 IL-13, 413–14
 IL-15, 443
 inflammation, 292
 Ly-1 positive, 23
 lymphopoiesis, 316
 lymphotoxin, 830
 maturation, 315
 blockade, 317
 ontogeny, 237
 osteoprotegerin, 875
 proliferation, 238
 RANK, 875
 TGF β -mediated apoptosis,
 1139–40
- B-lymphocyte chemoattractant/B cell
 attracting chemokine 1 *see* CXCL13
- bacille Calmette–Guérin (BCG), 587,
 589
- Bambi (BMP and activin membrane-
 bound inhibitor), 1124–5, 1156
- basic fibroblast growth factor (bFGF),
 132, 1164
- basophils
 IL-4 production, 233
 IL-5 activity, 272
- β_c expression, 209–10
- Bcl-2
 activin, 1161

- Bcl-2 (*continued*)
 apoptosis, 898, 1138
 CD95-induced apoptosis, 898
 erythropoietin effects, 155
 expression regulation
 by IL-2, 181–2
 by IL-4, 238
 by IL-15, 444
 FGF regulation of expression, 765
 FGFR signaling, 767
 IL-7, 313
 IL-12, 392
 TGF β -induced up-regulation, 1136
 TGF β -mediated apoptosis, 1138
 TGF β signaling, 1137
- Bcl-X_L
 erythropoietin effects, 155
 expression regulation
 by IL-2, 181–2
 by IL-15, 444
 TGF β -induced up-regulation, 1136
 TGF β -mediated apoptosis, 1138
 TGF β signaling, 1137
- BCRF1, 606, 611, 1218
 behavior, prolactin effects, 133
 betacellulin (BTC), 959, 972–4
 activities, 973–4
 gene, 973
 precursor processing, 973
 protein, 972
 receptors, 973
- betaglycan, 1121, 1122, 1157
see also TGF β receptors, type III
- BFU-E (burst-forming unit-erythrocyte), 152, 153, 154, 1164, 1165
- big-big prolactin, 117
 big-prolactin, 117
 β_{IL-3} , 209, 210–11
 bindarit, 1094–5
- bioassays, 1377, 1378, 1379–81
 advantages, 1381
 cell function induction, 1380–1
 cytotoxicity assays, 1380
 pitfalls, 1381
 proliferation measurement, 1380
 specificity, 1381
 synergism of cytokines, 1381
 two-step procedure, 1381
 types, 1379–81
- birds
 chemokines, 68, 69, 70
 FGE, 76
 IL-1, 62–3
 IL-2, 64–5
 IL-3, 65–6
 IL-4R α , 71
 IL-6, 66–7
 IL-8, 68, 69, 70
 IL-11R α , 71
 IL-13R α , 71
 IL-15, 70
 IL-16, 71
 IL-17R, 71
 IL-18, 70–1
 IL-21R, 71
 IL-22R, 71
 interferons, 59–61
 PDGF, 76
 stem cell factor, 65–6
 TGF β , 74
 TNE, 72
- birth, IL-1R α , 678
- blood
 IL-1R α , 677
 umbilical cord and stem cell factors, 1013
- blood transfusion, 1267
 platelets, 374
- BMP, 1179–83
 clinical applications, 1182–3
 embryogenesis, 1182
 fractures, 1183
 isolation, 1180
 limb morphogenesis, 1182
 pathophysiology, 1182
 pleiotropy, 1181–2
 signaling, 1124, 1125
 Smads, 1182
 structure, 1180–1
- BMP receptors, 1159, 1182, *Plate 51.1*
 signaling, 11, 1182, *Plate 51.1*
- BMP2, 1180, 1181, 1182
 recombinant, 1182–3
- BMP3, 1180, 1181, 1182
- BMP4, 1180, 1181
 osteosarcoma, 1182
- BMP7 *see* osteogenic protein 1 (OP-1)
- BMP11, 1181
- BMS2.4, 550
- bone
 formation, 1179, 1180
 fractures, 1183, 1281
 giant cell tumor, 879
 heterotopic formation, 1182
 IL-1R α , 689–90
 estrogen action, 682
 gene therapy, 695
 IL-11 effects, 367–8
 IL-18, 713
 loss in osteoporosis, 878–9
 metabolism and IL-5, 273
 metastatic disease, 879–80
 non-union, 1183
 osteoclastic resorption, 494
 RANK, 876
 RANK-associated disorders, 877–8
 resorption, 494
 tumor-associated osteolysis, 879–80
 VEGF in formation, 1025
- bone gla protein *see* osteocalcin
- bone marrow
 Flt3, 994–5
 G-CSE, 527, 530
 IL-3, 215
 IL-5, 269, 270
 IL-7, 322
 IL-11, 368
 stem cell factor, 1012
 stromal cells, 527, 550
- bone marrow transplantation
 acute myeloid leukemia, 512
 G-CSE, 1225
 GM-CSE, 510, 511, 512, 513, 1225
 IL-7, 327, 1226
 IL-10, 611
 rhIL-11, 375
 IL-12, 396–7
- bone morphogenetic protein *see* BMP
- Bottazzo–Feldmann hypothesis, 1192
- brain
 CX3CL1, 1106–7
 erythropoietin function, 159
 IL-1R α , 680, 688
 IL-2R, 436
 IL-3, 205
 IL-7, 323
 IL-15, 436
 IL-17, 497
 M-CSE, 945
 TGF α expression, 966
- brain injury
 IL-1R α gene therapy, 694–5
 ischemic, 497, 847
 TNE, 847–8
- breast, HGF in development, 789
- breast and kidney/B cell- and monocyte-activating chemokine *see* CXCL14
- breast cancer
 angiogenesis, 1220
 CXC chemokines, 1069–70
 human cell line, 125
 IL-18, 722
 prolactin, 136
 PTHrP, 880
 stem cell factor, 1014
- breast tumors, GH overexpression, 106

- brefeldinA, 1387
 bronchogenic carcinoma, IL-1Ra, 683
 bullous pemphigoid, 419
- C chemokines, 1049
 cachexia, 1221, 1223
 inhibins, 1155
 calcium
 IL-18, 712
 metabolism and prolactin, 134
 calpain, 181
 cancer, 1213–26
 activin, 1161
 angiogenesis, 1281
 animal models, 1221–2
 antiangiogenesis clinical trials,
 1285, 1286–9
 cachexia, 445, 1155, 1221, 1223
 counter current invasion theory,
 892, 1093, *Plate 38.1*
 CSF-1, 943
 CXC chemokines, 1069–70
 CXCL10, 1063
 cytokine gene transfer, 1341–2
 cytokine inhibitors, 1222–3
 cytokine polymorphisms, 1219
 cytokine relationship, 1214–16
 cytokine signaling blocking, 1222–3
 cytokine therapy novel strategies,
 1226
 FGF, 758, 759–60, 763–4
 FGFR, 766
 Flt3, 1000–1
 GM-CSF, 1269
 immunotherapy, 512
 HGF, 789–91
 IFN- γ in tumor rejection, 585–6
 IL-1F7 antitumor activity, 742
 IL-1Ra, 683
 IL-6, 1220, 1222–3
 IL-7, 323–8
 IL-10, 1220
 IL-11, 369
 use, 1225–6
 rhIL-11 pharmacology, 373–4
 IL-12 therapy, 395, 397–8, 585
 IL-13, 419
 IL-15, 449, 451, *Plate 53.4*
 antitumor therapy, 452
 IL-17, 490–1
 IL-18, 721–2
 immunotherapy, 324, 328
 inflammation, 1214–15, 1221–2
 inhibin, 1155, 1161
 M-CSF, 947
 MCP-1, 1222
 MET, 795, 796, 797
- MIF, 1042, 1043, 1215–16,
Plate 45.4
 NF κ B, 1215, *Plate 53.2*
 p53, 1215–16
 prognosis and MET, 795, 797
 proto-oncogenes, 1219–20
 stem cell factors, 1014–15
 supportive therapy, 1225–6
 T cells, 1224
 TGF α , 966
 TGF β , 1220
 therapy, 1224–6
 TNF, 849–50
 susceptibility, 851
 TNF- α , 1215, 1222, *Plate 53.2*
 TRAIL/Apo2L, 865
 therapeutic use, 866
 tumor-associated osteolysis of
 bone, 879–80
 tumor progression, 1216–20
 vaccines, 1224, 1226
 VEGF, 1026–7
see also chemotherapy; metastases;
named cancers; radiotherapy
- cancer cells
 CC chemokines, 1092–4
 CD95 downregulation, 893
 CD95L, 892–3
 epiregulin, 975
 GM-CSF, 1269
 HB-EGF, 971–2
 IL-4, 244–5
 IL-4R, 250
 IL-8, 1057
 IL-11, 367
 IL-15, 433, 434, 436, 449
 IL-18, 719
 M-CSF, 945–6
 metastasis, 1220–1
 canstatin, 1286
 carboxyamido-triazole (CAI), 1285,
 1289
 carcinogenesis, 1213–14
 classification, 1214
 cytokines, 1216–20
 treatment strategies, 1214
 cardiac hypertrophy, HB-EGF, 972
 cardiac myxoma, IL-6, 291, 292
 cardiostrophin (CT-1), 1263
 cardiovascular disease
 angiogenesis, 1282
 IL-1Ra, 681–2, 689
 gene therapy, 695
 cardiovascular system, TNF, 848
 cartilage
 IL-17, 493
 IL-18, 713
- caspase-1 *see* ICE
 caspase-3, 1138
 activation, 1140
 CD95, 899
 substrate, 1140
 caspase-8, 865–6
 activation, 900
 CD95, 897, 898, 899, 900, *Plate 38.2*
 inhibition, 900
 inhibitor, 891–2
 caspase-9, 1138
 caspase-10, 865–6
 CD95, 897
 caspase cysteine protease, 1140
 caspase inhibition, 899–900
 caspase recruitment domains
 (CARD), 844
 Castleman's disease
 anti-IL-6 receptor antibody, 294
 IL-6, 1222–3
 abnormal production, 292
 caveolin 1 (Cav-1), 1125
 c-Cbl, CSF-1, 935
 Cbl insulin receptor substrate, 129
 CC chemokine(s), 1049, 1083–95
 agonists, 1084, 1086–7
 chicken, 70
 dendritic cells, 1090–1
 inflammation, 1087
 inflammatory, 1084, 1086
 lymphocyte traffic, 1091–2,
 Plate 47.2
 production regulation, 1087–8
 small antagonists, 1095
 structure, 1086
 therapeutic targets, 1094–5
 transcriptional activation, 1094
 tumor cells, 1092–4
 CC chemokine receptor, 8, 9, 1084,
 1085, 1086–7
 antagonists, 1095
 cancer, 1092
 coupling, 1089–90
 expression regulation, 1089–90
 CC21, 1084
 CCL1, 1088
 CCL2 *see* monocyte chemoattractant
 protein 1 (MCP-1)
 CCL3, 1084, 1088
 dendritic cell production, 1091
 CCL3L1, 1084, 1089
 CCL4, 1084, 1088
 CCL5, 1084, 1088, 1089
 antagonist action, 1095
 cancer, 1092
 dendritic cell production, 1091
 transcriptional activation, 1094

- CCL7, 1084
 antagonist action, 1095
 dendritic cell attraction, 1094
- CCL8, 1084
- CCL9, 1091
- CCL10, 1091
- CCL11, 1084, 1086, 1088, 1089
- CCL13, 1084
- CCL14, 1088
- CCL15, 1088
- CCL16, 1088
- CCL17, 1088, 1102
 cancer, 1092
 T cell traffic, 1091, 1092
- CCL18, 1088, 1091
- CCL19, 1084, 1088, 1091
- CCL20, 1084, 1090
- CCL21, 1088, 1091
 dendritic cell attraction, 1094
- CCL22, 1088, 1089, 1102
 cancer, 1092
 dendritic cell production, 1091
 T cell traffic, 1092
- CCL24, 1086
- CCL26, 1086
- CCL27, 1091
- CCR1, 1086, 1089
 dendritic cell expression, 1090, 1091
 expression regulation, 1089
- CCR2, 1086, 1089–90
 cancer, 1092
 dendritic cell expression, 1090
- CCR3, 1086, 1087, 1088, 1089
 T_{H2} cell associated, 1091–2,
Plate 47.2
- CCR4, 1086, 1087, 1088
 T_{H2} cell associated, 1091–2,
Plate 47.2
- CCR5, 894, 1086, 1087, 1089
 dendritic cell expression, 1090, 1091, 1092
 expression regulation, 1089–90
 HIV infection, 1087
 T_{H1} cell associated, 1091–2,
Plate 47.2
- CCR6, 1087, 1090
 dendritic cell expression, 1091
- CCR7, 1087, 1090–1, 1091
 cancer, 1069–70, 1093
- CCR8, 1086, 1087, 1088
 T_{H2} cell associated, 1091–2,
Plate 47.2
- CCR9, 1087
- CCR10, 1087
- CCR11, 1087
- CD4, 468, 469, 894
- CD4⁺ T cells
 autoimmune disease, 1191
 cancer, 1224
 gene therapy, 1342
 CD95/CD95L, 893, 894
 differentiation, 314
 HIV infection, 893–4
 IFN- γ , 568, 570
 IL-2, 169, 1304
 IL-4, 231, 240–1, 246
 IL-7, 318
 IL-7R, 311, *Plate 13.3*
 IL-8, 1061–2
 IL-12 cancer therapy, 395
 IL-13, 413
 IL-15, 450, 452
 IL-16, 466, 467, 468–9
 IL-17, 478
 IL-18, 718
 immune response, 187
 T-cell homeostasis, 332
- CD8⁺ T cells
 autoimmune disease, 1191
 cancer gene therapy, 1342
 differentiation, 314
 IFN- γ , 568, 570
 IL-2, 1304
 IL-4, 232, 246
 IL-4 expression, 240–1
 IL-7, 318
 IL-7R, 311, *Plate 13.3*
 IL-8, 1061–2
 IL-12 cancer therapy, 395
 IL-15, 442, 450, 452
 IL-16, 466, 467
 IL-18, 718
 T-cell homeostasis, 332
 tumor eradication, 327–8
 tumor resistance, 1224
- CD8_{ED}, 210
- CD14, 811, 815
- CD16, 450
- CD16_{ED}, 211
- CD19, 317
- CD23, 238
- CD25, 650
- CD26, 1089, 1095
- CD26/DPP IV, 1088–9
- CD28, 1303
- CD30, 232
- CD34, 317
- CD34⁺ stem cells, 327
 G-CSF, 532
 IL-15, 441
- CD40, 232, 238
 B cell activation, 239–40
 monocyte inflammatory pathway,
 615
- signaling pathway, 239
 TGF β -mediated apoptosis of B
 cells, 1139–40
- CD40–CD40L interaction, 386
- CD40L, 242, 243, 386, 1303
- CD44, 445, 797
- CD56, 450
- CD69, 271
- CD80, 231
- CD86, 231, 238
- CD95
 antisense oligonucleotides, 1364
 apoptosis, 891–2, 893, 896, 897–8,
 900, *Plate 38.2*
 FADD, 896–7, 900, 901
 signaling, 893
 T cell receptor, 890–1
 T cells, 891
- CD95/CD95L
 autoantibody production
 prevention, 891
 autoimmune disease, 894–5
 CD4⁺ T cells, 893, 894
 diabetes mellitus type 1, 895
 experimental autoimmune
 encephalomyelitis, 895
 Hashimoto's thyroiditis, 895
 hepatocytes, 892
 liver, 892
 multiple sclerosis, 894–5
 negative selection, 891
 signaling, 888
 IL-18, 719, 722
- CD95 receptor, 885, **888–902**
 apoptosis, 892, 893, 897–8, 899
 B cells, 891
 caspase-8, 897, 898, *Plate 38.2*
 caspase-10, 897
 down-regulation in cancer cells, 893
 expression regulation, 888–9
 FADD, 896–7, 900
 function, 889–902, *Plate 38.1*
 HIV infection, 893–4
 immune system, 889–92
 internalization, 900
 signaling, 896–901, *Plate 38.2*
 activation, 900
 alternative pathways, 899
 inhibition, 899–900
 inhibitor, 893
 initiation, 896–7, *Plate 38.2*
- Stat proteins, 889
 stimulation-induced clustering,
 900
 structure, 888–9
 T cells, 889, 893–4, 900–1
 thymocytes, 891

- CD95L, 711, **885–902**
 AP-1, 887
 apoptosis, 890, 892, *Plate 38.1*
 cancer cells, 892–3
 CTL, 888, 890, *Plate 38.1*
 expression
 IL-18, 719
 regulation, 886–7
 function, 889–902, *Plate 38.1*
 immune system, 889–92
 infection, 892
 membrane-bound, 887–8
 NF κ B, 887
 signaling, 888
 soluble, 887–8
 structure, 886
 T cells, 887
 TILs, 893
 transplant rejection, 892
- CD154, 448
- celiac disease
 IL-15, 448
 TNF, 851
- cell adhesion molecules, 1269
- cell-associated signals, xxiii
- cell cycle repressors, 556
- cell proliferation, activin, 1159, 1161, 1166
- cellular immunity, IL-12, 392
- central nervous system (CNS)
 CX3CL1, 1106–7
 CX3CR1 expression, 1108–9
 FGFs, 757, 762
 IL-1Ra, 678
 gene therapy, 694–5
 IL-18, 713
 TNF, 846–8
 tumors and IL-4, 249
- cerebral palsy
 IL-9, 355
 IL-18, 724
- cervical cancer
 IL-17, 490
 TNF, 851
- CFR, 749, 750
- CFU-E, 152, 153, 1164, 1165
- Chagas disease, 1192
- chemokine(s), xxiii
 amphibians, 68
 antisense oligonucleotides, 1366
 birds, 68, 69, 70
 CD26/DPP IV, 1088–9
 constitutive, 1087–8
 fish, 67–8
 IL-15, 442, 444
 IL-17 induction, 486
 inducible, 1087–8
- lymphoid microarchitecture
 formation, 830
 nomenclature, 5, 7, 1050
 phylogeny, 67–8, 69, 70
 production stimulation, 13
 protein structure, 1051, 1053
 receptors, 1050
 T cells, 1091–2, *Plate 47.2*
see also named subgroups
- chemokine receptors, 8, 9, 1052
 antisense oligonucleotides, 1366
 functional decoy, 1090
 human, 1058–60
 nomenclature, 5, 7, 1050
 signal transduction, 1058–9
 subclasses, 8, 9
- chemotactic and angiogenic factor (CAF), 68
- chemotherapy
 Flt3, 997
 G-CSF, 532, 1225
 GM-CSF, 513, 1225, 1269
 management of neutropenia, 510, 511
 IL-11, 1225–6
 rhIL-11 pharmacology, 373, 374
 mucositis, 512
- cholesterol metabolism, 1094, 1095
- cholinergic anti-inflammatory pathway, 853
- chondroblasts, 1179
- chondrocytes
 IL-1Ra gene therapy, 694
 proteoglycan synthesis reduction, 1364
- chordin, 1181, 1182, *Plate 51.1*
- choriomammosomatotropin genes, 103
- ciliary neurotrophic factor (CNTF), 385
- ciliary neurotrophic factor receptor (CNTFR), 1263
- circadian regulation, TGF α , 966
- CIS (cytokine-inducible SH2-containing protein), 90–1
 IL-2 signaling, 183
 IL-9 signaling, 358
 prolactin effects, 129–30
- CLL22, 1089
- clotting inhibition, phosphorothioate oligonucleotides, 1356, 1357–8
- CNS-1 (conserved noncoding sequence 1), 229
- COL-3, 1285, 1288
- colitis, IL-7, 322
- collagen fragments, 1286
- colon/colorectal cancer
 angiogenesis, 1220
- CXC chemokines, 1069
 Flt3 treatment, 1000
 IL-1Ra, 683
 IL-7, 322, 323, 326
 NSAID protection, 1215
- colony-forming unit-granulocyte macrophage (CFU-GM), 351
- colony-forming unit-macrophage (CFU-M), 283
- colony-stimulating factor(s) (CSFs), xxiii, 3, 4
 phylogeny, 65–6
- colony-stimulating factor 1 (CSF-1)
 adaptor proteins, 935
 cAMP, 937
 biochemical responses, 929–37
 cancer, 943
 c-Cbl, 935
 cleaving, 991
 clinical detection, 942–3
 cytoskeleton, 937
 delivery models, 945–6
 exons, 992
 c-Fms, 937–41
 G protein, 933
 inflammation, 942–3, 945
 JAK–STAT pathway, 936
 Na⁺/H⁺ antiport activity, 933–4
 phosphatases, 935–6
 phospholipase, 932–3
 PI3K, 934–5
 PKC, 933
 Ras activation, 930–1
 S6 kinase, 933
 signaling, 941–2
 structure, 992
 tyrosine phosphorylation, 934–7
 ubiquitination, 935
 Vav proto-oncogene, 937
see also macrophage colony-stimulating factor (M-CSF)
- colony-stimulating factor 1 receptor (CSF-1R), 929–30, 937–42
- colorectal cancer *see* colon/colorectal cancer
- complement activation, phosphorothioate oligonucleotides, 1356, 1357
- condyloma acuminatum, 557
- connective tissue growth factor (CTGF), 1024
- contact dermatitis
 IL-1Ra, 681
 IL-17, 497
- coronary artery disease, CX3CR1, 1110
- corticosteroids, MIF expression, 1038
- counter current invasion theory, 892, 1093, *Plate 38.1*

- CPT-11, 446
 CRF2-4, 612
 CRF2 orphan receptors, 612, 613, 614
 IL-22, 632
 Crohn's disease
 activin, 1167–8
 anti-TNF α therapy, 1199, 1201
 CX3CL1, 1104, 1106
 cytokine system, 1196
 IL-1Ra, 683
 IL-4 gene, 230
 IL-6, 293
 IL-10, 609
 IL-15, 448
 IL-16, 470
 IL-18, 713
 ISIS 2302, 1358–9
 cryptic self hypothesis, 1192
 CTLA-8, 475, 476, 477, 550
 gene, 475, 476
 murine, 477
 Cushing's syndrome, 661
 CX3C chemokine(s), 1049
 CX3C chemokine receptor, 8, 9, 67
 CX3CL1, 1088, **1101–13**
 chemokine domain, 1103, 1104,
 Plate 48.3
 chemokine receptor-dependent
 cell adhesion, 1112
 chromosomal localization, 1102–3
 CNS, 1106–7
 dendritic cell production, 1091
 expression, 1104, *1105*, 1106–7,
 1112
 function, 1110–11
 gene structure, 1102–3, *Plate 48.1*
 protein sequence/structure,
 1103–4, *Plate 48.2*
 role, 1112
 virally encoded, 1111
 CX3CR1, 1101–2
 antagonists, 1111
 expression, 1107–9
 function, 1110–11
 gene, 1103
 polymorphisms, 1110
 regulation, 1107–9
 role, 1112–13
 signaling pathways, 1109–10, 1112,
 Plate 48.4
 CX3CR1-binding proteins, 1111
 CXC chemokine(s), **1049–70**
 birds, 68, 69, 70
 cancer, 1069–70
 ELR⁺, 1050, 1063–4
 genes, 1050, *1051*
 glomerulonephritis, 1068
 human
 biologic properties, 1060–3
 production, 1056–8
 infection, 1065–6
 MIF induced, 1043
 modifications in mice, 1063–4
 pathology role, 1065–70
 pulmonary disease, 1067–8
 reperfusion injury, 1066–7
 rheumatoid arthritis, 1068–9
 skin disease, 1067
 CXC chemokine receptor, 8, 9
 birds, 68, 69, 70
 fish, 67, 68
 human, *1052*, 1058–60
 CXCL1, 1055, 1057, 1061, 1062
 cancer, 1069
 contact hypersensitivity, 1067
 glomerulonephritis, 1068
 infection, 1066
 psoriasis, 1067
 rheumatoid arthritis, 1068
 CXCL2, 1055, 1057, 1061, 1062
 cancer, 1069
 contact hypersensitivity, 1067
 glomerulonephritis, 1068
 psoriasis, 1067
 rheumatoid arthritis, 1068
 CXCL3, 1055, 1057, 1061
 psoriasis, 1067
 CXCL4, 1054, 1057
 biologic properties, 1062
 cancer, 1069
 CXCL5, 1057–8, 1062
 cancer, 1069
 glomerulonephritis, 1068
 rheumatoid arthritis, 1068
 CXCL6, 1055, 1058, 1061, 1062
 cancer, 1069
 cleaving, 1089
 CXCL7, 1054–5, 1057, 1061, 1062
 cancer, 1069
 infection, 1066
 CXCL8 *see* IL-8
 CXCL9, 1055, 1058, 1062–3, 1286,
 1287
 allograft rejection, 1306
 cancer, 1069
 contact hypersensitivity, 1067
 psoriasis, 1067
 CXCL10, 1055–6, 1058, 1062–3
 antisense oligonucleotides, 1367
 cancer, 1069
 contact hypersensitivity, 1067
 infection, 1066
 modifications in mice, 1064
 psoriasis, 1067
 pulmonary fibrosis, 1068
 CXCL11, 1056, 1062–3
 CXCL12, 1056, 1058, 1060, 1089
 biologic activity, 1063
 cancer, 1069, 1070
 metastases, 1220
 modifications in mice, 1064–5
 pulmonary fibrosis, 1067
 rheumatoid arthritis, 1068–9
 CXCL13, 1056, 1058, 1063
 dendritic cell production, 1091
 modifications in mice, 1065
 rheumatoid arthritis, 1069
 CXCL14, 1056
 CXCL16, 1091, 1111
 CXCL18, 1056
 CXCL25, 1055
 CXCR genes, 68
 IL-13, 414
 CXCR1, *1052*, 1059, *Plate 47.2*
 cancer, 1069
 CXCR2, *1052*, 1059, *Plate 47.2*
 agonists, 1094
 cancer, 1069, 1094
 infection, 1065, 1066
 modifications in mice, 1064
 CXCR3, *1052*, 1059, *Plate 47.2*
 agonists, 1088
 ligands, 1062–3
 modifications in mice, 1064
 T-cell accumulation in skin
 disease, 1067
 T_{H1} cell associated, 1091–2,
 Plate 47.2
 CXCR4, 894, *1052*, 1059–60, *Plate 47.2*
 cancer, 1069–70, 1093
 expression, 1063
 infection, 1066
 metastases, 1220
 modifications in mice, 1064–5
 rheumatoid arthritis, 1068–9
 CXCR5, *1052*, 1060, *Plate 47.2*
 modifications in mice, 1065
 CXCR6, *1052*, 1060
 CXCR8, *Plate 47.2*
 CXL16, 1112
 cyclin-dependent kinase (CDK), 1132,
 1160
 cyclin-dependent kinase inhibitors
 (CKIs), 556, 581
 cyclin pathway, activin, 1160
 cyclo-oxygenase 2 (COX-2), 494
 HGF stimulation, 791
 IL-1, 643
 cysteine-rich FGF receptor *see* CFR
 cytochrome c, 1138
 cytokine(s)

- activity, xxiv
antagonism, 12–13
bioactivity, 1377–8
cell surface receptor binding, 1376
definition, 5
detection in cells/tissues, 1386–9
diagnostic tools, xxv
diversity generation, 288, *Plate 12.5*
features, 5–6
gene therapy, xxvi
importance, xxv
inhibitors, 1384
inhibitory actions on cytokine production, 13
measurement, 1376–8
 in body fluids, 1378–84
 cellular supernatants, 1378–84
molecular philosophy of actions, 12
monocyte-derived, 4
networks, 11–14, 1195
nomenclature, xxv, 5
phylogeny, 57–76
pleiotropy, 12, 20, 1376
polymorphisms, 1219
production, 6, 20
profile, 1376, 1384–5
profiling, 1378
recombinant, xxiv, xxvi
redundancy, 288, 1378
signaling, 85–94
staining for proteins, 1386–7, *Plate 61.4*
stimulatory actions on cytokine production, 13
structural features, 7
synergism, 12–13, 1381
therapeutic administration, xxvi
transcript detection, 1387–8
in vitro production, 1385–6
cytokine gene transfer, 1335–45
therapeutic applications, 1341–5
vectors, 1336–41
cytokine receptors
 chains, xxiv–xxv
 class I, 8, 9
 Box 1/Box-2 regions, 8, 9
 signaling, 10
 subfamilies, 8, 9
 class II, 8, 9
 families, 8, 9
 trans-signaling, 14
 transmodulation, 13–14
cytomegalovirus (CMV)
 IL-8, 1062
 IL-10, 606, 607
 IL-18, 720
 TRAIL/Apo2L therapeutic use, 866
cytoskeleton, CSF-1, 937
cytotoxic T cells (CTL), 232
 CD95L signaling, 888, 890, *Plate 38.1*
 ELISPOT frequency analysis, 1389
 IL-6-induced differentiation, 283
 IL-7-induced, 326
 IL-12, 392
cytotoxic T lymphocyte-associated antigen-8 *see* CTLA-8
cytotoxicity assays, 1380
D6, 1087
Dab2, 1131
Daf-1, 1122–3
DAN, 1182, *Plate 51.1*
DARC, 1087
Daxx protein, 899
DC3, 325
death-associated protein (DAP) kinase, 844
death-induced signaling complex (DISC), 865, 897, 898, 900, *Plate 38.2*
decoy receptor 3 (DcR3/TR6), 889
defensins, 1090
dendritic cells
 CC chemokines, 1087, 1090–1, 1094
 cross-priming, 1342
 CSF-1, 943–4
 CX3CL1, 1106
 Flt3, 999–1000, 1001, 1002
 follicular, 322
 GM-CSE, 507, 509
 IL-1 family, 647
 IL-2, 170
 IL-4
 activation, 249
 signaling, 236, 242
 tumor site, 248
 IL-10, 1322
 IL-15, 443–4
 IL-18, 712
 lung, 1324
 RANK, 876–7
 RANKL, 873
 T cell differentiation, 1319, 1324–6
dendritic epidermal T cells (DTEC), 320, 321
diabetes mellitus, insulin-dependent
 CD95/CD95L, 895
 IL-1Ra, 683, 690
 gene therapy, 695
 IL-1RI, 661
 IL-6, 292
 IL-10, 610
 IL-18, 722
 pathogen association, 1192
 TNF, 852
disease development, 19
 cytokine role, 1344
 infectious, 20–1
 severity differences, 21
 susceptibility differences, 21
 in vitro disease association studies, 32–52
DNA
 non-viral vectors, 1340–1
 vaccines, 1344
DR3, 24
Drosophila, Toll, 813–14, 816, *Plate 33.3*
dwarfism, 106
E-cadherin, 797
E2F-1, 556
E2F-4, 556
early response genes (EGR) 1–3, 887
ECRF3, 1066
ELISA, 1378, 1382–3
 conjugated antibody, 1383
 matrix effects, 1383
 sandwich, 1382, *Plate 61.2*
ELISPOT frequency analysis, 1388–9, 1390, *Plate 61.6*, *Plate 61.7*
embryogenesis
 BMP, 1182
 FGFs, 755, 756
 HGF–MET interactions, 794–5
 VEGF, 1024–5
embryonic implantation, IL-1Ra, 678
endocrine hormones, xxiii
endoglin, 1121, 1122, 1282
 see also TGFβ receptors, type III
endoplasmic reticulum
 LSP–IL-15, 437
 SSP–IL-15, 436, *Plate 18.1*
endostatin, 1282, 1283, 1284
 gene therapy, 1290
endothelial cell-derived neutrophil attractant-78 *see* CXCL25
endothelial cells
 CX3CL1, 1104, 1106
 CX3CR1 expression, 1108
 FGF2 release, 750
 GM-CSE, 507
 IL-4 effects, 243–4
 IL-15, 445
endothelial leukocyte adhesion molecule 1 (ELAM-1), 243

- endotoxin
tolerance, 818
see also lipopolysaccharide (LPS)
- enhanced chemoluminescence
technique, 1385
- enzyme-linked immunosorbent assay
see ELISA
- eosinophil-derived neurotoxin
(EDN), 271
- eosinophil differentiation factor
(EDF), 264
- eosinophilia, 269–70
airway, 418, 1320
biological specificity, 269
- eosinophils
activation, 271
asthma, 1315
GM-CSF, 507
IL-3 production, 206
IL-4, 233, 243
IL-5 role in production, 269–70
IL-9, 351–2
IL-13, 415
IL-17, 496
MIF expression, 1038
production
in vitro, 269–70
in vivo, 270
tissue localization, 271–2
- eotaxin, 272, 1086, 1092
- eotaxin-2, 272
- eotaxin-3, 272
- epidermal growth factor (EGF), 3, 4, 322
activities, 962, 963–4
discovery, 962
family, 959–76
genes, 961, 963
precursor processing, 960–1
proteins, 959–60, 962–3
receptors, 963
structure, 963
TGF β -mediated apoptosis, 1138
TGF β signaling, 1132, 1134
transmembrane precursor protein, 962
see also named members
- epidermal growth factor receptor
(EGFR), 797, 959–60, 961
amphiregulin, 969
BTC binding, 973
cell migration, 971
epigen binding, 976
epiregulin binding, 975
inhibitors in cancer therapy, 1222
knockout mouse studies, 962
TGF α , 966
- epigen, 959, 975–6
receptors, 976
- epiregulin, 959, 974–5
receptors, 975
- epithelial cells
airway and IL-16, 467
CX3CL1, 1106
IL-4 effects, 244
IL-9, 352
IL-13, 415, 416
- Epstein–Barr virus (EBV)-associated
lymphoma, 1217, 1218–19
- Epstein–Barr virus (EBV) and IL-10,
606, 611, 629, 1217, 1218–19
- Epstein–Barr virus-induced gene 3
(EBI-3), 385, 388, 394–5
- Erb signaling network, 959
- Erb1, 963
- Erb2, 963
- Erb4, 963
- ErbB, 961
- ErbB receptors, 961
- ErbB2, 961
TGF α , 966
- ErbB2/neu receptor, 1220
- ErbB3, 961
BTC binding, 973
- ErbB4, 961
BTC binding, 973
- epiregulin binding, 975
- HB-EGF, 971
TGF α , 966
- ERK (extracellular regulated kinases),
129
IL-3-induced activation, 213
IL-17, 481
MIF signaling, 1044
TGF β -induced activation, 1136
TNF production, 840
VEGFR1 signaling, 1023
VEGFR2 stimulated, 1024
- Erk-1, 213, 1132
- Erk-2, 213
- erythrocytes, 152, 153
- erythroid burst-forming units
(BFU-E), 1164, 1165
- erythroid colony-forming units
(CFU-E), 152, 153, 1164, 1165
- erythroid progenitor cells, 351
- erythropoiesis
GATA, 156–7
inhibition, 152
- erythropoietin, xxiii, 149–59
alpha-form, 151
beta-form, 151
cancer/cancer therapy, 1225
clinical studies, 157–8
clinical use, 151, 158, 1225
FGF2 combination, 763
function, 153
gene, 149–50
expression, 151–2
kidneys, 151
c-kit down-regulation, 208–9
liver, 151
misuse by athletes, 1267
nervous system, 159
production, 151–2
recombinant human, 150–1,
157–8
red cell production stimulation,
1267
side effects, 158
site of action, 152
stem cell factor synergy, 1012
structure, 149–51
- erythropoietin mimetic peptides
(EMPs), 154
- erythropoietin receptor, 10, 153–4
active sites, 154
inactive dimers, 126
signaling, 154–7
Stat proteins, 155
structure, 153
- estrogens
bone action and IL-1Ra, 682
prolactin receptor upregulation,
125
- etanercept, 852, 1199–200
- expansile skeletal hyperphosphatase, 878
- experimental autoimmune
encephalomyelitis (EAE)
antisense oligonucleotides, 1367
CD95/CD95L, 895
CX3CL1, 1106–7
CX3CR1, 1109
IL-1Ra, 688
IL-1RI, 653
IL-10, 609–10
IL-18, 722
- extracellular matrix
FGF actions, 747, 748, 750
FGF binding, 753–4
hematopoietic progenitor cell
cytokine response modulation,
1265
- eye, TGF α expression, 966
- eye disease
angiogenesis, 1282
neovascular and FGFs, 758, 763
- eye infection
CD95L, 892
MIF, 1042

- familial expansile osteolysis, 878
- Fanconi anemia
Flt3, 997
IL-6 deficiency, 284
- Fas *see* CD95
- Fas-associated death domain protein (FADD), 827, 844
activin, 1161
CD95, 896–7, 900, 901
- Fas-associated phosphatase 1 (FAP1), 899
- FasL *see* CD95L
- Fc γ receptor type I (Fc γ R-1), 579
- Felty's syndrome, 532
- fetal liver kinase 2 *see* flk-2
- FGF1, 750
angiogenesis, 757–8, 761
disease associations, 759, 763
embryogenesis, 755–6
expression, 754
features, 759
FGFR signaling, 767–8
neovascular disease, 763
rheumatoid arthritis, 759, 763
wound healing, 761–2
- FGF2, 750, 751–3, *Plate 31.1*
angiogenesis, 757–8, 761
apoptosis regulation, 765
Bcl-2 expression regulation, 765
cancer, 758, 759, 763–4
disease associations, 759, 763, 769
ECM binding, 753, 754
embryogenesis, 755–6
expression, 754, 755
inhibition, 769
features, 759
FGFR signaling, 768
GM-CSE, 763
hematopoiesis, 762–3
HIV infection, 764–5
integrin expression, 761
MAPK activation, 761
MMPs, 754, 761, 762
neovascular disease, 758, 763
rheumatoid arthritis, 759, 763
VEGF synergy, 764, 765
wound healing, 761–2
- FGF3, 749–50, 751, *Plate 31.1*
angiogenesis, 758
embryogenesis, 755–6
features, 759
- FGF4
angiogenesis, 758
embryogenesis, 755–6
features, 759
hematopoiesis, 763
organogenesis, 756
- FGF5, 759
- FGF6, 759
- FGF7
angiogenesis, 758
ECM binding, 753
features, 760
wound healing, 762
- FGF8, 754
features, 760
organogenesis, 756
- FGF9, 760
- FGF10
features, 760
organogenesis, 756
wound healing, 761–2
- FGF11–14, 760
- FGF12, 756
- FGF15, 760
- FGF16–19, 760
- FGF17, 756, 760
- FGF20, 760
- FGF21, 760
- FGF22, 760
- FGF23, 760
- FGFR1, 752, 765
skeletal development
abnormalities, 766
- FGFR2, 765
skeletal development
abnormalities, 766
- FGFR3, 765
skeletal development
abnormalities, 766
- FGFR4, 765
- fibrinogen, 817
- fibroblast growth factor (FGF), 3, 4, 747–71
amphibians, 75
angiogenesis, 757–8, 758, 761
angiogenic, 755
apoptosis regulation, 765
birds, 76
cancer, 758, 759–60, 763–4
chromosomal location, 749
CNS, 757, 762
disease associations, 758, 759–60, 763–5
ECM
actions, 747, 748, 750
binding, 753–4
embryogenesis, 755, 756
export mechanisms, 749–50
expression, 748, 754–5, 755
eye neovascular disease, 758, 763
family, 748–54
fibrosis, 758
fish, 75
functions, 755–8, 759–60, 761–3
gene-knockout studies, 755–6
genes, 748–9
hematopoiesis, 757, 762–3
HIV infection, 764–5
Tat protein, 764–5, 769–70
identification of novel, 769
intracellular trafficking, 750–4, 751, 752–3
invertebrates, 74–5
Kaposi's sarcoma, 758, 759, 763, 764, 765
MMPs, 754, 761, 762, 764
neovascular disease, 758, 763
nervous system, 757, 762
neurodegenerative disease, 758
NLS, 749, 750, 751, *Plate 31.1*
nuclear trafficking, 751–2
organogenesis, 756
production, 749–50
protein sequence, 749
proteins
endogenous, 751–2
exogenous, 752–3
regulation, 754–5
rheumatoid arthritis, 758, 759, 763
secretion mechanisms, 749–50
specificity, 768–9
structure, 748–9, 759–60, *Plate 31.1*
subcellular localization, 750–4
Tat protein, 764–5, 769–70
vasculogenesis, 756–7
VEGFs, 757, 761
wound healing, 757, 761–2
see also basic fibroblast growth factor (bFGF); *individual named* FGFs
- fibroblast growth factor-binding protein (FGF-BP), 764–5
- fibroblast growth factor receptors (FGFR), 747, 748, 752
amphibians, 75
birds, 76
cancer, 766
dimers, 766, 767, *Plate 31.2*
disease associations, 766
expression, 765–6
fish, 75
inhibitory mechanisms, 768
regulation, 765–6
signaling, 766–8, *Plate 31.2*
skeletal development
abnormalities, 766
specificity, 768–9
structure, 765, *Plate 31.1*
see also individual named FGFRs

- fibroblasts
 CXC chemokines, 1062
 G-CSF, 527
 GM-CSF, 507
 IL-4, 243
 signaling, 236
 IL-13, 416
 IL-16, 467
 IL-17, 488–9, 495
 MIF expression, 1038
- fibrodysplasia ossificans progressiva, 1182
- fibronectin, 817, 1135, 1163
- fibrosis
 activin, 1163
 FGFs, 758
- filamin, 1130
- fish, 57
 chemokines, 67–8
 FGF, 75
 IL-1, 61–2
 IL-2, 63–4
 IL-3, 65
 IL-6, 66
 IL-8, 67–8
 IL-13, 71
 interferons, 58, 60
 PDGF, 76
 TGF β , 73–4
 TNE, 71–2
- FKBP12, 1124
- FLASH (FLICE-associated huge protein), 899
- c-FLIP, 891, 893, 898–9, 901
- v-FLIP, 898
- flk-2, 989–90
- flow cytometry, 1386, 1387, 1390,
Plate 61.5
 multicolor, 1387, *Plate 61.5*
- flt-3/flt-2 receptor tyrosine kinase, 1264
- Flt1 *see* vascular endothelial growth factor receptor 1 (VEGF-R1)
- Flt3, **989–1004**
 adjuvant properties, 1001–2
 cancer, 997–9, 1000–1
 clinical uses, 1002–4
 colon cancer treatment, 1000
 dendritic cells, 1001, 1002
 regulation, 999–1000
 expression, 993
 gene, 992–3, 1220
 gene therapy, 1003
 hematopoietic cell development, 994–6
 hematopoietic disorders, 996–7
 immune response, 1001–2
- immunotherapy, 1003–4
- infectious diseases, 1001
- isoforms, 991–2
- leukemia, 997–9
- ligand cloning, 990–1
- liver transplantation, 1002
- radiation therapy, 1003
- stem cells
 expansion, 1002–3
 mobilization, 1003
 structure, 992
 tissue regeneration, 1003
 tolerance induction, 1001–2
 tyrosine kinase inhibition, 998, 1223
- Flt3 receptor, 990, 992–3
 expression, 993–4
- Flt4 *see* vascular endothelial growth factor receptor 3 (VEGF-R3)
- c-Fms
 activating mutations, 938
 dimerization, 937–8
 Grb2, 941
 internalization, 938
 KI domain, 940
 PI3K, 941
 Src, 941
 Stat1, 941
 tyrosine phosphorylation, 938–42
 Y807, 940
 Y809, 939–40
 Y973, 940–1
- fms-like tyrosine kinase 3 *see* flt3
- focal adhesion kinase, 129
- follicle-stimulating hormone (FSH) regulator, 1155
- follicular dendritic cells (FDC), 322
- follistatin, 1153, 1155–7
 activin, 1159
 branching morphogenesis, 1162–3
 production activation, 1167
 variant forms, 1156
 wound healing, 1164
- follistatin-related protein (FSRP), 1155, 1156
 function, 1157
 wound healing, 1164
- c-*fos*, 11
 expression regulation by IL-2, 181–2
- fowlpox virus (FPV), 59, 60, 61
 genome, 71
- fractalkine *see* CX3CL1
- fractalkine receptor *see* CX3CR1
- fractures
 angiogenesis, 1281
 BMPs, 1183
- FRIL, 991
- fungal infection, M-CSF, 946, 947
- G protein
 CSF-1, 933
 dissociation, 11
- G-protein-coupled receptor (GPCR) signaling, 970
- G3139, 1359
- Gab1, 798
- gap junctions, 323
- gastric carcinoma, 1069
- gastrointestinal ischemia, 376–7
- gastrointestinal mucosal atrophy, 377
- gastrointestinal mucositis, 374–5
- gastrointestinal tract
 antisense inhibitors, 1361
 BTC activity, 973
 EGF, 964
 IL-1Ra, 683, 690
 IL-18, 713
 nucleases, 1361
 TGF α , 966, 967
see also colon/colorectal cancer;
 Crohn's disease; inflammatory bowel disease; ulcerative colitis
- GATA-1, 156–7
- GATA-2, 157
- GATA-3, 157, 229
 asthma, 1324–5
 IL-5 gene expression, 266, 267
 IL-13 gene expression, 410
 IL-13-induced activation, 418
 T_{H2} cells, 236, 266
 differentiation, 1324–5
- γ_c (common cytokine receptor γ chain), 173
 expression, 175
 IL-2 signal transduction, 176–7, 185–6
 Jak3 association, 186
 regulation, 175
 negative by proteolysis, 181
 regulatory elements, 171
 SCID-X1, 186
 signaling molecule association, 177–81
 gene arrays, 1385
 gene polymorphisms of human cytokines, 25–9
 gene therapy, **1335–45**
 applications, 1341–5
 approaches, 1336–41
 cytokine function identification, 1344–5
 gene transfer vectors, 1336–41
 non-viral, 1340–1

- viral, 1337–40
- genetic markers, 22
- genetics of cytokines, 19–24, 25–52
 - gene polymorphisms, 20
 - genetic variation, 24
 - in vitro* studies
 - disease association, 32–52
 - expression, 30–1
- genomic regions, 19
- genomics for cytokines, 1389
- giant cell tumor of bone, 879
- giantism, 106
- glial cell-derived neurotrophic factor (GDNF), 288, 1122
- glioblastoma, 1220
- glioma, 419
- glomerulonephritis
 - chronic hepatitis B, 1244
 - CX3CL1, 1104
 - CXC chemokines, 1068
 - IL-6, 292
 - MIF, 1042
- Glu-110, 268, 269
- glucocorticoids, 481
 - chemokine receptors, 1090
 - RANKL, 875
- glucose homeostasis, abnormal, 106
- gonadotrophin-releasing hormone (GnRH), 132
- gonads, prolactin effects, 132
- Goodpasture's syndrome, 1191
- gp130, 67, 288, *Plate 12.4*, *Plate 12.6*
 - cell growth induction, 290
 - IL-6R, *Plate 22.5*
 - IL-11 signaling, 369, 371–2
 - signal transduction pathways through, 289–91
- gp130 receptor family, 1263
- graft-*versus*-host disease (GVHD), 375, 1376
 - IL-1Ra, 683–4, 690, 691
 - IL-10, 611
 - IL-12, 396–7
 - IL-18, 719, 722
- graft-*versus*-leukemia, 375
- granulocyte chemotactic protein 2 *see* CXCL6
- granulocyte colony stimulating factor (G-CSF), 525–38
 - biochemical properties, 526
 - biologic activities, 530
 - cancer therapy, 532, 1225
 - clinical uses, 532–3
 - deletion, 530–2
 - ex vivo* stem cell expansion, 1271, 1272
 - gene
 - cloning, 526
 - expression, 526–8
 - promoter elements, 527
 - structure, 526–8
 - transcription, 527
 - IL-4, 242
 - IL-17-enhanced, 488, 489
 - ligand, 534
 - maternal/fetal interface, 527–8
 - myelodysplastic syndromes, 158
 - neutrophil stimulation of
 - production, 1268
 - pro-inflammatory cytokine actions, 537–8
 - protein, 526
 - recombinant human, 532, 533
 - side-effects, 532
 - stem cell mobilization, 1269–70
 - structure, 526, *Plate 22.1*
 - therapeutic use, 1257
- granulocyte colony stimulating factor (G-CSF):granulocyte colony stimulating factor receptor complex, 534, *Plate 22.4*
- granulocyte colony stimulating factor (G-CSF) receptor, 525
 - acute myeloid leukemia, 534
 - alternative splicing of human transcript, 529–30
 - biochemical properties, 528
 - deletion, 530–2
 - differentiation mediation, 535
 - gene, 528–9
 - growth mediation, 535
 - isoforms, 529–30
 - JAK kinases, 535
 - ligand interaction, 534, *Plate 22.4*
 - pathology associated with altered expression, 533–4
 - PI3K, 537
 - protein structure, 528, *Plate 22.2*
 - signal transduction, 530, 534–7, *Plate 22.5*
 - constitutive in leukemogenesis, 538
 - SOCS, 536
 - Stat proteins, 535–6
 - transcription regulation, 530
 - tyrosine phosphorylation, 535, *Plate 22.5*
- granulocyte-macrophage colony stimulating factor, human (hGM-CSF), 156
- granulocyte-macrophage colony stimulating factor, human (hGM-CSF) receptor, 156
- granulocyte-macrophage colony stimulating factor (GM-CSF), 503–14
 - β_c subunit deficient mice, 508
 - cancer therapy, 512, 1225, 1269
 - clinical applications, 510–12, 513, 514
 - deficiency
 - in humans, 509–10
 - mouse models, 508
 - disease models, 509
 - DNA vaccination, 1344
 - eosinophilia, 270
 - ex vivo* stem cell expansion, 1271, 1272
 - gene
 - expression, 504–5
 - IL-3 gene relationship, 506
 - regulation, 504–5
 - hematopoiesis with FGF2, 763
 - IL-2 combination, 1226
 - IL-3 association, 201, 202, 208
 - IL-5 expression induction, 270
 - IL-6 synergy, 283
 - IL-17 induction, 486, 488
 - c-kit down-regulation, 208–9
 - myelodysplastic syndromes, 158
 - neutrophil stimulation of
 - production, 1268
 - pharmacokinetics, 514
 - pharmacologic administration, 508–9
 - protein structure, 504
 - side effects, 514
 - stem cell factor synergy, 1012
 - stem cell mobilization, 1269–70
 - therapeutic use, 1257
 - TNF- α induction, 486
 - toxicity, 514
 - transgenic mice, 507
 - in vitro* activity, 506–7
 - in vivo* activity, 507–9
- granulocyte-macrophage colony stimulating factor receptor (GM-CSF-R), 211, 505, 1262
 - genetics, 506
 - signal transduction, 505–6
 - Stat proteins, 506
 - subfamily, 8, 9, 13
- granulocytes, 1257
 - GM-CSF 507
 - IL-4 effects, 243
- granulocytic precursor cells, G-CSF effect, 530
- granulopoiesis, G-CSF/G-CSFR system, 531
- Graves' disease, 419
 - cytokine system, 1196

- Graves' disease (*continued*)
 IL-16, 470
 tissue damage, 1191
- Grb-2, 212–13, 941
 CSF-1, 935
- gremlin, 1182
- groa-γ* *see* CXCL
- growth factors, 3–4, 6, 7
 hematopoietic, xxiii, 3
 IL-6 function, 285–6
 phylogeny, 73–6
- growth hormone (GH), 103–9
 disease states, 106
 gene, 103–4
 immune function, 107, 108
 overexpression, 106
 production, 105–6
 control, 104
 protein, 104–6
 skin, 108–9
 stress modulation, 107
 therapeutic administration, 106
- growth hormone (GH) receptors,
 106–9
- growth promoting activity (GPA), 67
- GTPases, 657
- guanylate-binding protein 1 (GBP-1),
 93, 579, 761, 769
- Guillain-Barré syndrome, 680
- Hashimoto's thyroiditis
 CD95/CD95L, 895
 cytokine system, 1196
 tissue damage, 1191
- Helicobacter pylori*, 495
- helminth infections
 CC chemokines, 1087
 IL-9, 354
 IL-13, 417
- hematological malignancy
 angiogenesis, 1281
 erythropoietin, 158
 IL-15, 449
- hematopoiesis, 1255, 1256
 activin, 1164–5
 deterministic regulation, 1258,
 1259–60
 extrinsic regulation, 1260–2
 FGFs, 757, 762–3
 IL-3 effect, 207–9
 IL-4 effect, 242
 IL-6, 283–4
 IL-12, 393
 IL-13, 416
 IL-17, 488–9
 intrinsic regulation, 1260–2
 lineage selection/commitment,
 1260, 1261–2
- process, 1257–62
 prolactin effects, 134, 135
 stochastic regulation, 1258, 1259
 stress, 208–9
- hematopoietic cell development and
 Flt3, 994–6
- hematopoietic cytokines, 1255–72
 clinical use, 1267–72
 neutrophil production
 stimulation, 1268
 platelet production stimulation,
 1268–9
 red cell production stimulation,
 1267
 stem cell mobilization, 1269–70
- hematopoietic growth factors, xxiii, 3
- hematopoietic progenitor cells, 1265,
 1266
 adhesion molecules, 1265
 GM-CSF, 506
 IL-9, 351
 receptor activity modulation, 1266
 renewal, 1258–60, 1260–1
 responses to cytokines, 1262–5
 antagonists, 1266–7
 inhibitors, 1266–7
 modulation, 1265–7
 suppression, 1266–7
 VEGF, 1025–6
- hematopoietic progenitor kinase 1
 (HPK1), 1133
- hematopoietic stem cells, 314, 1256
 commitment, 317
 differentiation, 317
ex vivo expansion, 1270–2
 Flt3, 1003
 G-CSF, 532–3
 renewal, 1258–60, 1260–1
 VEGF, 1025–6
- hematopoietin family, 7
- hematopoietin receptor superfamily,
 1262–4
- heparan sulphate, 753, 1265–6
- heparan sulphate proteoglycans
 (HSPGs), 747, 748, 749, 750
 ECM, 753–4
 FGF trafficking, 752–3
 FGFRs, 765, 766
 dimers, 767
 HB-EGF, 969
 MMP reservoir, 754
 VEGF binding, 1022
- heparin, 1266
 VEGF binding, 1022
- heparin-binding EGF (HB-EGF), 959,
 960, 969–72
 activity, 962, 971–2
- cancer, 971–2
 gene, 971
 precursor processing, 970–1
 protein, 969–70
 receptors, 971
 signaling, 970
- hepatitis
 IFN- α therapy, 1238–51
 IL-15, 448
 IL-18, 722
- hepatitis B
 acute, 1240, 1241–2
 advanced cirrhosis, 1244
 chronic, 1240–1
 anti-HBeAg-positive, 1243–4
 antiviral therapy, 1242
 HBeAg-positive, 1242–3
 extrahepatic disease, 1244
 fulminant, 1242
- IFN
 treatment, 1237–8
 type I, 557
 IFN- α therapy, 1238–45
 IFN- β therapy, 1245
 IFN- γ therapy, 1244–5
 immunosuppressed patients, 1244
 vaccine, 512
- hepatitis C
 acute, 1246
 antiviral treatment, 1245–50
 chronic, 1246
 cirrhosis, 1250
- IFN
 treatment, 1238
 type I, 557
 IFN- α therapy
 combination with ribavirin,
 1246–7
 pegylated, 1247–9
 IL-12 therapy, 398
 liver transplantation, 1250
 viral kinetics, 1249–50
- hepatitis D, 1251
- hepatocellular carcinoma, 795, 796
- hepatocyte growth factor (HGF), 310,
783–99
 active, 784
 activin, 1159, 1163
 angiogenesis, 791
 autoimmune disease, 791
 cancer, 789–91
 co-receptors, 797
 crystal structure, 786
 disease states, 789–91
 embryogenesis, 794–5
 expression, 788–9
 gene

- organization, 787
 promoter, 787–8
 human, 783–4
 inflammatory bowel disease, 791
 kringle domains, 786, 787, *Plate 32.1*
 latent, 784
 nervous system, 789
 protein sequence, 785, *Plate 32.1*
 signaling, 797–8
 skeletal muscle generation, 788–9
 structure, 784, *Plate 32.1*
 TGF β synergy, 1132
 tubulogenesis, 789, 798
 ulcer-healing, 791
 variant forms, 786
see also MET
 hepatocyte growth factor-like protein, 786
 hepatocyte growth factor (HGF) receptor, 1263, 1264
 hepatocytes
 apoptosis, 865
 CD95/CD95L, 892
 IL-4 effects, 244
 TGF β -mediated apoptosis, 1138–9
 hereditary hemorrhagic telangiectasia, 1122
 herpes simplex virus (HSV)
 gene transfer vectors, 1340
 IL-15, 451, 453
 IL-18, 720
 herpesvirus
 human, 441
 saimiri *see* HVS
 see also human herpesvirus 8 (HHV8)
 HIF-1, 152, 1021
 hip replacement, total, 368
 histamine-producing cell stimulating factor (HCSF), 207
 HIV-associated lymphoma, 1217–18
 HIV-based vectors, 1338
 HIV infection
 apoptosis, 893–4
 CC chemokine antagonists, 1095
 CCR5, 1087
 CD4⁺ T cells, 893–4
 CD95 receptor, 893–4
 CX3CL1, 1107
 CX3CR1, 1110
 CXCL12, 1063, 1066
 CXCR4, 1066
 FGF2, 764–5
 GM-CSF, 511, 513
 IL-2, 469
 IL-7, 330
 IL-12 therapy, 398
 IL-15, 450–1
 IL-16, 469–70
 IL-18, 720
 M-CSF, 946
 progression rate, 22
 Tat protein, 764–5, 769–70, 887, 894
 HLA-A, 851
 HLA-B, 851
 HLA-DP, 851
 HLA-DQ, 851
 HLA-DR, 851
 HLA-DR2, 850
 HLA-DR3, 850
 HLA-DR4, 135, 850
 HMG box, 915–16
 HMGB1, 916–17, 918
 HMG (high mobility group) proteins, 914
 HMGB1, 913–21
 amino acid sequences, 914
 antagonists, 918
 autoimmune disease, 920
 cellular localization, 914–15
 cytoplasmic, 915
 endotoxin stimulation, 916–17
 extracellular roles, 919
 HMG boxes, 916–17, 918
 inflammatory responses, 917
 lethal systemic inflammation mediation, 916–18
 MAPK, 920
 NF κ B, 920
 nuclear, 914–15
 post-translational modification, 916
 RAGE interaction, 918–20
 release, 919
 rheumatoid arthritis, 920
 sepsis, 918
 sickness behavior, 917–18
 structure, 915–16
 t-PA, 918
 tissue injury, 917–18
 HMGB-1 receptors, 918–20
 HMGB-2, 915
HOG-1 stress gene, 660
 homeostasis maintenance, xxiii
 hormones
 polypeptide, 6, 7
 sex, 125, 682, 1190
 steroid, 119–20
 see also glucocorticoids
 host defense
 IL-1Ra, 678, 696–7
 IL-18, 720
 innate, xxiii
 host response, 1040
 hsp60, 817
 hsp65, 1192
 hsp70, 817
 HSV-1, 451
 HTLV-1
 IL-2, 1216–17
 IL-9, 350, 353
 IL-15, 449, 451
 leukemia, 1216–17
 human chromosome 9, 550
 human chromosome 19, 551
 human GH-variant (hGHV), 103
 human herpesvirus 8 (HHV8)
 CC chemokines, 1093
 CX3CR1, 1111
 CXC chemokines, 1066
 multiple myeloma, 1217
 see also Kaposi's sarcoma
 human herpesvirus infection, 441
 human prolactin-binding protein, 121
 human prolactin receptor gene, 121–2
 human T cell lymphotropic virus *see* HTLV-1
 humoral immunity, IFN- γ , 584–5
 HVS, 486
 CXC chemokines, 1066
 genome, 476
 IL-26, 636
 ORF-13, 477
 HVS-13, 475, 476, 479, 486
 HVS-14, 476
 hypercalcemia of malignancy, 880
 hypereosinophilic syndrome, 1376
 hypergammaglobulinemia, 23
 hyperprolactinemia, 120–1, 125
 stress-induced, 133–4
 hypersensitivity
 contact
 CXC chemokines, 1067
 IL-1Ra, 681
 delayed-type
 autoimmune disease, 1343
 IL-16, 470
 hypoestoxide, 494
 hypoxia-induced factor-1 *see* HIF-1
 hypoxia response element (HRE), 1020–1
 hypoxic conditions, IL-8, 1057
 ICE, 648, 649, 650
 IL-18, 711, 712
 inhibition, 712, 900
 TNFR1, 845
 IFN- α , 7, 549–50, 1233–51
 allograft rejection, 1298–9

- IFN- α , 7 (*continued*)
 anti-inflammatory properties, 1235
 antiangiogenic activity, 1285, 1286, 1287
 cancer gene therapy, 1342
 hepatitis C therapy, 1246–7
 hepatitis D, 1251
 host defense, 1235–7
 IL-10 regulation, 608
 IL-11 down-regulation, 366
 IL-18R induction, 715
 immunotherapy in cancer, 1225
 pegylated, 1247–9, 1250–1
 side effects of therapy, 1250–1
 structure, 552, *Plate 23.1*
 therapeutic use, 1225, 1238–51
 viral hepatitis therapy, 1238–9, 1240–4, 1245–50
- IFN- α/β , 549
 antagonism with IFN- γ , 12
 family, 7
 proteins, 4
- IFN- α/β receptors, 8, 9, 10
- IFN- β , 549–50
 anti-inflammatory therapy in autoimmunity, 1200–1
 antiangiogenic activity, 1286
 hepatitis B therapy, 1245
 multiple sclerosis therapy, 12
 structure, 552, *Plate 23.1*
- IFN- δ , 552
- IFN- γ , xxiv, 4, 567–90
 allografts
 acceptance, 1303–5
 rejection, 1299–300, 1307
 antagonism
 with IFN- α/β , 12
 with IL-4, 12
 antiangiogenesis, 1286, 1287
 antigen presentation, 582–3
 antiproliferative activities, 581, 586
 antisense oligonucleotides, 1362
 antiviral activity, 580–1
 apoptosis, 586
 asthma, 1318, 1322–3, 1324
 B cells, 585
 biologic activities, 580–6
 biosynthesis, 569–70
 birds, 60
 cytokine stimulation, 13
 erythropoiesis inhibition, 152
 FGF2 expression, 755
 gene, 567–8, 569
 promoter elements, 568
 hepatitis B treatment, 1244–5
 humoral immunity, 584–5
- Ig heavy chain switching, 585
 IL-10 regulation, 608
 IL-12-induced production, 388, 389, 390, 396
 IL-12 receptor regulation, 389
 IL-18-induced, 570, 717
 innate immunity, 581–2
 LPS induction, 24
 macrophage activation, 581–2
 MHC class I, 586
 MHC class II, 24
 multicolor flow cytometry, 1387, *Plate 61.5*
 nickel dermatitis, 497
 NK cells, 569–70
 production stimulation, 13
 protein, 568, 569, 569
 regulation, 567–8
 signaling protein disruption, 586–7
 Stat1-dependent genes, 579–80
 structure, 569
 synergism with TNF, 12
 T cells, 326, 568, 569, 570, 583–4, 1323
- T_{H1} cells, 583–4
 T_{H2} cell inhibition, 232
 TNF receptor expression modulation, 14
 tumor immunity, 585–6, 1224
 vaccine adjuvant use, 61
- IFN- γ -inducible protein 10 *see* CXCL10
- IFN- γ receptor, 8, 9, 10, 570–2
 JAK kinases, 573–7
 signal transduction, 569, 573–9
 alternative pathways, 579
 dysfunction, 586–7, 588, 589–90
 Jak–Stat pathway, 574–9
 Stat inhibitors, 577–8
 ubiquitin–proteasome pathway, 578
- SOCS, 576–7, 578
 Stat proteins, 573–8, 579
 subunits, 570–2, 574
 expression/regulation, 578–9
- IFN- γ -regulated genes, 579–80
- IFN-inducible T-cell α chemoattractant *see* CXCL11
- IFN κ , 550
- IFN-R α , 553, 554
- IFN-R β , 553–4
- IFN regulatory factor (IRF), 1234
- IFN stimutable genes (ISGs), 1234
- IFN-stimulatable response element (ISRE), 1234
- IFN-stimulated gene factor 3 (ISGF-3), 1234
- IFN- τ , 7, 551
 structure, 552, *Plate 23.1*
- IFN- ω , 7, 549–50
- IFNGR subunits, 570–2, 574, 578–9
 deficiency in humans, 587, 588, 589–90
 deficient mouse models, 587
 tumor regulation, 586
- Ig heavy chain switching, IFN- γ , 585
- Ig repeats, 815
- IgA
 eosinophil degranulation, 271
 IL-5 enhancement of production, 273
 IL-6 increase in production, 282–3
- IgA nephropathy, 451
- IgE
 asthma, 1315, 1319
 IL-4 isotype switching, 239–40
 synthesis
 IL-4, 282, 414
 IL-6, 282
 IL-13, 414
- IGF-1
 GH secretion regulation, 104–5
 production, 106
- IGF-1 receptors, 106–9
 immune function, 107, 108
- IgG, 239, 292
- IgM, 238, 239
- I κ B, 1044
- I κ B kinase (IKK) complex, 10, 11
 IL-10, 616
 VEGF, 1027
- IL-1, xxv, 4
 amphibians, 62
 anti-TNF α therapy, 1199
 antiangiogenesis, 1287
 birds, 62–3
 blocking, 661–3
 cachexia, 1223
 chromosomal localization, 736–7, 738
 cytokine production stimulation, 13
 erythropoiesis inhibition, 152
 family, 643–63
 biochemical actions, 658
 cells producing, 647
 cytoplasmic signaling cascades, 657–9
 F5–F10, 735–44
 members, 645–51
 signal transduction, 657–61
 structures, 646–7
 fish, 61–2
 gene, 736–7, 738

- human disease, 644
IL-2 receptor expression
 modulation, 14
IL-10 regulation, 608
inflammation, 643
NF κ B inhibition, 1202
nomenclature, 5
ovulation, 678
pyrogen assay, 1377
rheumatoid arthritis, 1195–6
TLR-like signals, 815
TNF receptor downregulation, 14
see also IL-18
- IL-1 receptor, 8, 9
 amplification, 658
 binding, 660
 birds, 63
 blockade, 661–3
 cellular specificity, 658
 deficiency, 644
 fish, 62
 genes coding for, 653–4
 R1–9, 653–4, 1365
 rheumatoid arthritis, 1196
 signal transduction, 10–11, 655,
 735, 817–18, 1196
 Toll homology, 814, *Plate* 33.3
 type I, 654–6, 735
 cytoplasmic domain, 659
 gene regulation, 656–7
 human studies, 661–3
 soluble, 661–3
 surface expression, 656–7
 type II, 653, 656, 676
 decoy, 735
 see also IL-1F; IL-1Ra
- IL-1 receptor-activating kinases *see*
 IRAKs
- IL-1 receptor antagonist *see* IL-1Ra
- IL-1 α , 644, 645–6, 650–1
 antisense oligonucleotides, 1364
 autoantibodies, 651
 autocrine growth factor, 650
 deficiency, 644
 deficient mice, 651–2
 human systemic response, 662–3
 membrane, 650–1
 precursor, 650
 receptor binding, 655, 656
 transcriptional regulation, 647, 648
- IL-1 α receptor, 650, 651
- IL-1 β , 644, 645–6
 activin, 1166–7
 birds, 62, 63
 converting enzyme, 649, 650
 deficiency, 644
 deficient mice, 651, 652
- FGF2 expression, 755
 fish, 61–2
 function, 1345
 IL-1 α production control, 652
 polymorphisms, 1219
 production, 647
 receptor binding, 655, 656
 rheumatoid arthritis, 1344
 secretion, 649–50
 structure, 738, *Plate* 30.5
 transcriptional regulation, 647–8
- IL-1 β -converting enzyme *see* ICE
- IL-1F, 5
- IL-1F5, 645–6, 736, 737
 expression, 739–40, 743
 properties, 741
 protein sequence/structure, 738–9
 receptor binding, 743
 regulation, 740
 structure, 738, *Plate* 30.5
- IL-1F6, 736, 737
 expression, 740
 properties, 741
 protein sequence/structure, 738–9
 regulation, 740
- IL-1F7, 646, 736, 737
 antitumor activity, 742
 expression, 740, 743
 gene transfer, 744
 properties, 741
 protein sequence/structure, 738–9
 receptor binding, 743
 regulation, 740–2
- IL-1F8, 736, 737
 expression, 742
 properties, 741
 protein sequence/structure, 738–9
 regulation, 742
- IL-1F9, 736, 737
 expression, 742, 743
 properties, 741
 protein sequence/structure, 738–9
 receptor binding, 743
 regulation, 742
- IL-1F10, 736, 737
 expression, 742–3
 properties, 741
 protein sequence/structure, 738–9
 receptor binding, 743
 regulation, 743
- IL-1R-AcP, 654, 655, 657, 658
 IL-1R interaction, 676
- IL-1R-related proteins (IL-1Rrp), 736
- IL-1R1, 653, 1365
- IL-1R2, 653
- IL-1R3, 653
- IL-1R4, 653–4
- IL-1R6, 654
- IL-1R8, 654
- IL-1R9, 654
- IL-1Ra, 414, 643, 645–6, 669–98, 1196,
 1200
 animal models of disease, 686–90
 arthritis, 679–80, 687–8, 691–2
 gene therapy, 693–4, 696, 698
 autoimmune disease, 677, 679–80,
 687–8
 blood, 677
 bone, 682, 689–90
 cancer, 683
 cardiovascular disease, 681–2, 689
 gene therapy, 695
 CNS, 678
 gene therapy, 694–5
 combination therapy, 697–8
 crystal structure, 675–6
 delivery, 686, 697
 diabetes mellitus, 683, 690
 gene therapy, 695
 in disease, 679–84
 gastrointestinal tract, 683, 690
 gene
 allelic polymorphisms, 684–6
 structure, 670–1
 transcription regulation, 671–2
 gene therapy, 692–3
 animal models of disease, 693–6
 human trials, 696, 698
 host defense, 678, 696–7
 human trials, 690–2
 infection, 677, 679, 687, 690–1
 inflammation, 678
 inflammatory bowel disease, 683
 intracellular, 670, 673–4, 675, 677–8
 host defense, 697
 kidney disease, 682, 689
 gene therapy, 695–6
 lung disease, 681, 689
 gene therapy, 696
 mechanism of action, 675, 676
 nervous system, 680, 688
 normal physiologic function,
 677–8, 696–7
 organ transplantation, 683–4, 690,
 691
 osteoporosis, 682, 689–90
 ovaries, 678
 phosphorothioate
 oligonucleotide-induced, 1357
 production, 674
 protein isoforms, 672–4
 receptor binding, 655, 656, 675
 recombinant, 684
 reproductive system, 682

- IL-1Ra (*continued*)
 secretory, 670, 672
 sepsis, 687, 690–1
 skin, 680–1, 688–9
 soluble, 675, 677, 697
 therapeutic uses, 686
 tissue distribution, 676
 tissue localization, 674–5
- IL-1RI
 birds, 63
 deficient mice, 652–3
 fish, 62
 glycosylation, 655
- IL-1RI-associated kinase, 659
- IL-1RII, 62
- IL-2, xxv, 4, **167–88**
 actions, 170–2
 allografts
 acceptance, 1303–5
 rejection, 1297–8, 1305
 amphibians, 64
 anti-CD3 stimulation, 169, 170
 asthma, 1317, 1323–4
 B cell lymphoma cell lines, 170
 B cells, 171, 185
 birds, 64–5
 CD4⁺ T cells, 169
 cDNA cloning, 168
 chromosomal localization, 168
 CTTL-2 cell line bioassay, 1380
 cytokine stimulation, 13
 dendritic cells, 170
 DNA vaccination, 1344
 fish, 63–4
 function, 168–9
 gene
 chromatin remodeling, 170
 expression, 169–70
 genomic structure, 168
 GM-CSF combination, 1226
 HIV infection, 469
 HTLV-1, 1216–17
 IL-6 effects, 283
 IL-10 regulation, 608
 immune system, 170
 immunoglobulin secretion, 239
 immunotherapy
 cancer, 1224–5
 targeting, 186–7
 LAK cell induction, 325
 leukemia, 171, 1216–17
 lymphoma, 171
 NK cells, 171–2
 nomenclature, 5
 production stimulation, 13
 reptiles, 64
 signal transduction, 176–7, 440
 signaling pathways, 181–3
 structure, 168–9, *Plate 8.1*
 synergism with IL-5, 12
 T cells, 184, 185–6, 1304
in vivo effects, 445
- IL-2-activated genes, 181–3
- IL-2/IL-4 family, 7
- IL-2 receptor, 167, 1262–3
 chromosomal localization, 173
 classes, 168–9, 170–1, 172–3
 cloning, 173
 expression, 174–5
 modulation, 14
 γ subunit, 1263
 IL-2 signal transduction, 176
 immune system, 184–6
 immunotherapy targeting, 186–7
 LAK cells, 172
 regulation, 174–5
 signaling, 10, 177–81
 structure, 437
 subfamily, 8, 9
- IL-2R α , 172–3
 brain, 436
 expression, 174–5
 immune system, 184–5
 inhibitors in cancer therapy, 1222
 regulation, 174–5
 regulatory regions, 171, 174–5
 signaling molecule association, 177–81
 soluble, 183–6
 structure, 437
- IL-2R β , 172–3
 brain, 436
 expression, 175
 IL-2 signal transduction, 176
 regulation, 171, 175
 regulatory regions, 171
- IL-2R γ , 172–3
 gene, 185
see also γ_c (common cytokine receptor γ chain)
- IL-3, **201–17**
 administration, 207
 antagonists, 216
 apoptosis suppression, 215
 asthma, 1314
 B cells, 203, 204, 205–6
 birds, 65–6
 bone marrow stimulation, 215
 clearance, 202, 207
 clinical significance, 215–17
 eosinophilia, 270
ex vivo stem cell expansion, 1271, 1272
 FGF2 combination, 763
 fish, 65
 gene and GM-CSF gene relationship, 506
 glycoforms, 202
 hemopoiesis effect, 207
 hemopoietic stem cell actions, 203
 IL-5 expression induction, 270
 IL-6 synergism, 283
 IL-10 regulation, 608
 immune system, 207–8
 infection management, 216
 JAK kinases, 212, 214
c-jun, 215
c-kit down-regulation, 208–9
 leukemia, 216–17
 lung carcinoma, 216
 lymphoid cells, 204
 MAP kinase activation, 213
 mature cells of hematopoietic origin, 204
c-myc, 215
 neurons in brain, 205
 PI3K activity, 212, 213, 214–15
 platelet stimulation, 215
 progenitor cell actions, 203
 Ras activation, 212–13
 receptor binding, 211–12
 serum, 207
 signal transduction, 210–15
 sources, 206
 Stats, 214
 steady-state lymphohemopoiesis, 207–9
 stem cell factor synergy, 1012
 stress, 208–9
 structure, 201–3
 synergism with other cytokines, 203
 synthesized, 202–3
 T cells, 203, 204–5, 206, 216
 activation, 206–7, 208
 tyrosine phosphorylation, 212
- IL-3 receptor, 209–15, 1262
 β -chain, 209, 210
- IL-4, **227–51**
 allograft rejection, 1297–8, 1300, 1305
 gene therapy, 1343
 animal models, 245–9
 antagonism with IFN- γ , 12
 anti-tumor effects, 247–50
 antiangiogenesis, 1287
 antigen receptor triggering, 239
 antisense oligonucleotides, 1364
 asthma, 1314, 1316, 1317, 1319–20, 1323, 1325
 B cells, 230
 biologic effects, 237–40

- biologic properties, 237
cellular sources, 231–3
circulating IgE level regulation, 239
cytokine stimulation, 13
gene
 Crohn's disease, 230
 NRE regions, 229
 PRE-I region, 227–8
 regulatory sequences
 negative, 229–30
 positive, 227–9
 structure, 227–30
gene therapy, 248–9, 250
hematopoiesis effects, 242
IgE synthesis, 282, 414
IL-5 coexpression, 264–5
IL-10 regulation, 608
IL-12 production stimulation, 246
IL-12R, 389, 390
IL-13 relationship, 410, 411
inflammatory conditions, 497
inhibition by IFN- η , 585
isotype switching, 239–40
JAK kinases, 234, 1316
mediator production, 242–3
mRNA expression, 230
myelomonocytic cell effects, 242–3
neoplasia
 experimental model, 247–8
 gene therapy, 248–9
 neutralization, 1302, 1303
 NK cell effects, 241–2
 PI3K, 234, 235
 promoter, 228, 229
 protein, 230–1
 recombinant
 cancer models, 247–8
 clinical trials, 249–50
 signaling, 411
 in B cells, 235
 cascade, 234–6
 in T cells, 235–6
Stat3, 412
Stat6, 234–5, 236, 240, 1316
 binding site, 228–9
 structure, 227–31
T cells, 229, 230, 231–3, 412
 biologic effects, 240–2
 mature, 240–1
T_{H1} cells, 235–6, 241
T_{H2} cells, 235–6, 241, 412
T_{H2} differentiation, 1325
thymocyte effects, 240
TNF activity suppression, 841
toxin therapy, 250
tumor immunity, 248–9
- IL-4 receptor/receptor complex, 233–4, 247, 411, 412
 cancer cells, 250
 signaling pathway, 234
 soluble, 1327
 types I and II, 234
- IL-4R α
 antisense oligonucleotides, 1365
 birds, 71
 gene, 454
 variants and allergic disease, 234
- IL-5, 263–74
 antisense oligonucleotides, 1364
 asthma, 1314, 1315, 1316, 1317, 1319–20
 inhibition, 1327
 autoimmune disease, 272–3
 B cells, 272–3
 basophils, 272
 biological activities, 263–4
 bone marrow, 269, 270
 bone metabolism, 273
 eosinophil activation, 271
 eosinophilia, 269–70
 gene
 CLE0 sequence, 265–6
 coexpression, 264–5
 expression, 264–7
 GATA consensus site, 267
 IL-4/IL-5/IL-13 locus, 267
 NFAT site, 266–7
 posttranscriptional regulation, 267
 promoter region, 265–7
 regulatory elements, 266, 267
 response elements, 266
 structure, 264, *Plate 11.3*
 IgA production enhancement, 273
 IL-7-stimulated release, 316
 IL-9 synergism, 351–2
 mast cell secretion, 233
 nervous system, 273
 protein structure, 267–9, *Plate 11.3*
 receptor interaction, 268–9
 sources, 274
 synergism with IL-1, 12
 T cells, 263, 274
- IL-5 receptor, 268, 1262
- IL-6, 5, 281–94
 ACTH secretion, 285
 activin, 1166
 acute phase response, 284–5
 antagonist, 1200
 anti-TNF α therapy, 1199
 antisense oligonucleotides, 1364–5
 B cell malignancies, 1222
- B cells, 273, 282
B9 cell proliferation, 1379–80
biological activity, 282–6
birds, 66–7
cachexia, 1223
cancer, 1220, 1222–3
cardiac myxoma, 291, 292
Castleman's disease, 292, 1222–3
deficiency, 284
disease, 291–4
Fanconi anemia, 284
febrile response, 285
fish, 66
gene
 deregulated expression, 294
 promoter, 286–7, *Plate 12.1*
 promoter polymorphism, 22
 structure, 286–7, *Plate 12.1*
 growth arrest induction, 290
 growth factor function, 285–6
 hematopoiesis, 283–4
 IgA production, 282–3
IL-1 stimulation of
 glioblastoma/astrocytoma cells, 285
- IL-2 receptor expression
 modulation, 14
- IL-3 synergism, 283
- IL-4-dependent synthesis, 282
- IL-10 regulation, 608
- IL-11 relationship, 368, 369
- IL-17-induced, 488
- immune response, 282–3
- inflammation, 292
- inflammatory proliferative disease, 292–3
- inhibitors in cancer therapy, 1222–3
- invertebrates, 66
- multiple myeloma, 879, 1217, 1218, 1220, 1222–3
- myeloma cells, 293
- NF κ B, 287
 inhibition, 1202
- osteoclast development, 285
- phosphorothioate
 oligonucleotide-induced, 1357
- plasma cell neoplasia, 293–4
- production, 286
 stimulation, 13
- protein structure, 286–7
- receptor binding, 287, *Plate 12.3*
- responsive element, 289
- rheumatoid arthritis, 292–3, 1195
- Stat proteins, 289
- T cell activation, 283
- tumor microenvironment, 1220

- IL-6 receptor, 67, 287–8, 1263, *Plate 12.2*, *Plate 12.3*
 diversity generation, 288, *Plate 12.5*
 inhibitors in cancer therapy, 1222–3
 JAK–STAT signal transduction pathway, 289–91
 signaling, 10
 IL-10R signaling interaction, 615
 inhibitors, 291
 subfamily, 8, 9
- IL-7, **305–33**
 allograft rejection, 1305
 B cells, 314–18
 developmental gene up-regulation, 317
 bone marrow, 322
 transplantation, 327, 1226
 cancer, 322, 323–8
 therapy, 324–8
 cellular immune response, 331
 clinical importance, 315
 colitis, 322
 colorectal cancer, 322, 326
 CTL induction, 326
 developing tissues, 322–3
 expression, 309
 gene, 308, *Plate 13.1*
 cloning, 305–6, 308
 growth factor for DTEC, 321
 iIEL expression, 320–1
 IL-5 release stimulation, 316
 IL-10 regulation, 608
 immune response to infection, 328–31
 immune system, 321–2, 328–31
 immunodeficiency, 327
 immunotherapy, 324, 328, 330
 JAK tyrosine kinase, 312
 LAK cell induction, 325–6
 PI3K, 312
 proteolysis protection, 1266
 purification, 305
 SCID-X1, 311
 serum level elevation, 330
 skin immune reactions, 321
 Stat proteins, 312, 313, *Plate 13.2*
 structure, 306–7
 $\gamma\delta$ T cell homing, 321
 T cells, 318–21, 326
 homeostasis, 305, 331–2
 TCR, 319
 thymocytes, 332
 tissue-specific immune responses, 321–3
 tumor cell effects, 324
 IL-7-associated cytokines, 308, 310
- IL-7 receptor, 310–18, *Plate 31.2*
 B cells, 314
 signaling, 311, 312, 313, 327
 defective, 186
 T cells, 311, 314, *Plate 13.3*
 TCR γ , 313
- IL-7Ra, 310, 311, *Plate 31.2*
 anti-apoptotic effects, 313
 cancer, 323–4
 cell viability maintenance, 313
 developing tissues, 322–3
 gene rearrangement signals, 313
 lymphoma, 324
 RAG expression, 320
 Src kinase enzymes, 311–12, *Plate 13.2*
- IL-8, 1049, 1050, 1054, 1055
 angiogenesis, 1057
 anti-TNF α therapy, 1199
 antisense oligonucleotides, 1366
 AP-1, 1057
 ARDS, 1067
 asthma, 1068
 biologic properties, 1060–2
 birds, 68, 69, 70
 cancer, 1069
 cancer cells, 1057
 cytomegalovirus, 1062
 dendritic cell production, 1091
 fish, 67–8
 glomerulonephritis, 1068
 hypoxic conditions, 1057
 IL-1-induced, 659
 IL-17-induced, 488, 495
 infection, 1065, 1066
 inflammatory responses, 495
 MIF induced, 1043
 modifications in mice, 1063–4
 NF κ B, 1057
 inhibition, 1202
 production of human, 1056–7
 psoriasis, 1067
 pulmonary fibrosis, 1067–8
 receptor system, 1058–9
 reperfusion injury, 1067
 rheumatoid arthritis, 1068
 structure, 1054
 T cells, 1061–2
- IL-9, **347–58**
 asthma, 354–5, 1314, *1317*, 1320–1
 B cells, 349
 cerebral palsy, 355
 gene, 352–4
 cloning, 347–8
 expression, 353–4
 HTLV-1, 350, 353
 IL-5 synergism, 351–2
- IL-16 production stimulation, 467
 IRS-2, 357
 leukemia, 350, 351, 353
 lymphoma, 350, 351
 mast cells, 347
 parasitic infections, 354
 protein, 348
 responsive cells, 348–52
 T cells, 349–50, 353
 thymus, 350
- IL-9 receptor, 355–8
 characterization, 355–6
 JAK1, 356, 357
 JAK3, 356
 M-Ras, 357
 NF- κ B, 357
 signal attenuation, 357–8
 signal transduction, 356–7
 SOCS proteins, 358
 Stat proteins, 356–7
- IL-10, **603–19**
 actions, 605
 allograft rejection, 1300, 1305, 1306–7
 gene therapy, 1343
 angiogenesis, 610–11
 anti-inflammatory therapy in autoimmunity, 1200
 antiangiogenesis, 1287
 antisense oligonucleotides, 1362, 1365
 asthma, *1317*, 1321–2
 autoimmune disease, 605, 609
 gene therapy, 1342, 1343
 B cell malignancies, 1217–19
 cancer, 1220
 cellular, 606–7
 cellular functions, *618*
 chemokine receptors, 1090
 cytokine inhibition, 13, 417
 diabetes type 1, 610
 disease
 outcome, 23
 regulation, 617
 risk, 21
 expression, 607–8
 family, 7, **627–36**
 receptor redundancy, 636
 subfamily of homologues, 628–9
 gene, 23–4
 structure, 605–6
 human disease, 608
 IFN- γ inhibition, 570
 IL-12 inhibitor, 386
 IL-18 synergy, 717
 immune system, 605
 infectious disease, 20–21

- inflammation, 608–9
inflammatory bowel disease, 609
LPS induction, 24
pathophysiologic functions, 619
promoter, 608
protein structure, 605–6
receptor interaction sites, 606
recombinant, 21
regulation, 608
rheumatoid arthritis, 1195–6
SNPs, 23–4
structure, 606
systemic lupus erythematosus, 22–3
T cells, 607
TNF activity suppression, 841
transcriptional activation, 616
transcriptional regulation, 614–15
transgenic animals, 21
transplant rejection, 611
tumor progression, 1220
viral, 606–7, 611, 629
- IL-10 receptor, 8, 9, 636
disease states, 611–12
downstream genes, 617
expression, 612
inflammatory responses, 612
interaction sites, 606
JAK-Stat activation, 614–15
signaling, 604, 612, 613–15, 629–30
signaling pathway interactions, 615–16
SOCS, 616–17
Stat proteins, 614–15
structure, 612–13
- IL-10M1, 607
- IL-11, 363–78
activity, 363–4
anti-inflammatory therapy in autoimmunity, 1200
cancer therapy, 1225–6
cellular sources, 366
disease states, 368–9
down-regulation by IFN- α , 366
expression regulation, 368–9
gene
chromosome location, 364
downstream gene activation, 372
expression, 364–5
promoters, 365–6
structure, 364
suppressors, 365–6
IL-6 relationship, 368, 369
immunoreactive, 365
ligand, 370–1
MGF combination, 316
protein, 366
receptors, 369–71
recombinant human, 363, 366–8
gastrointestinal mucositis, 374–5
immunomodulation, 375–8
inflammatory bowel disease, 377–8
intestinal ischemia, 376–7
megakaryocytes, 371
pharmacology, 373–5
short bowel syndrome, 377
systemic inflammatory conditions, 376
rheumatoid arthritis, 1195–6
tissue expression, 366
in vitro activity, 366–8
- IL-11 receptor, 1263
distribution, 371
expression, 371
function, 372–3
signaling, 369, 371–2
structure, 369–70
- IL-11Ra, 71
- IL-12, 383–99
allograft rejection, 1298–300
angiogenesis, 393
antiangiogenic activity, 1285, 1287
asthma, 1324, 1325
B cells, 392–3
Bcl-2, 392
biologic activities, 391–3
bone marrow transplantation, 396–7
cancer, 585
gene therapy, 1342
therapy, 395, 397–8, 585
cellular immunity, 392
cellular sources, 385–6, 387
clinical trials, 397–8
cytokine stimulation, 13
deficiency in MSMD disorder, 590
gene, 383–4
gene therapy, 395
GVHD, 396–7
hematopoiesis, 393
IFN- γ production induction, 388, 389, 390, 396, 570
IL-10 regulation, 608
IL-15 antitumor combination, 452
IL-18 synergy, 717, 723
IL-18R induction, 715
infectious disease, 395–6
inflammation, 392
inhibitors, 386
LAK activity, 392
NK cells, 392
organ transplantation, 396, 397
production stimulation, 13
IL-4, 246
recombinant human, 397–8
regulation, 385–6
T cells, 392
T_{H1} differentiation, 1325
T_{H1}/T_{H2} response pattern, 391–2
tumor rejection, 585
- IL-12 receptor, 388–91
expression, 389
regulation, 390
IL-4 role, 389, 390
immune defects, 389–90
interactions with IL-12 family members, 390–1
signaling, 389
Stat proteins, 389
- IL-12RA, 385, 387–8
biologic functions, 394
IL-12R interaction, 390
- IL-13, 409–19
asthma, 417–18, 1314, 1316, 1317, 1319–20, 1322, 1323
autoimmune disease, 418–19
B cells, 413–14
biologic properties, 410
cancer, 419
cytokine inhibition, 13, 417
fish, 71
gene, 409–10
polymorphisms, 418
hematopoiesis, 416
IgE synthesis, 414
IL-1R antagonist, 414
IL-4 relationship, 410, 411
IL-5 coexpression, 264–5
IL-10 regulation, 608
IL-18
stimulation of production, 413
suppression of production, 720
immune response-induced pathology, 417–19
immune response regulation, 416–17
immune system, 416–19
inflammation, 416–17
mannose receptors, 415
NK cells, 413
production, 412–13
promoter, 22
protective immunity, 416
protein, 409–10
signal transduction, 411–12
skin, 418
Stat proteins, 410, 412, 1322

- IL-13 (*continued*)
 T cells, 412–13
in vitro biologic activities, 413
- IL-13 receptor, 247
 asthma therapy, 1327
 complexes, 410–11
- IL-13R α , 71
- IL-15, 431–53
 allograft rejection, 1297–8, 1305
 angiogenesis, 446
 autoimmune disease, 447–9
 B cells, 443
 biologic activities, 439–46
 birds, 70
 cancer, 443–4, 449, 451, 1221–2,
Plate 53.4
 antitumor therapy, 452
 CD8⁺ T cells, 442
 CD34⁺ stem cells, 441
 chemokines, 442, 444
 DNA vaccination, 1344
 expression regulation, 436–7
 gene, 432–3
 genomic organization, 432–3
 IL-10 regulation, 608
 IL-12 antitumor combination, 452
 immunotherapy, 451–3
 infection, 441, 452–3
 inflammation, 447–9
 isoforms, 436–7
 knockout animals, 446–7
 leukemia, 1221–2
 lymphocyte development
 regulation, 439–41
 NK cells, 440, 441–2, 451, 1214–15,
Plate 53.4
 prostate cancer, 443–4
- IL-15 receptor, 436
 distribution, 438
 MAPK pathways, 438
 PI3K, 438
 SHP-2, 438
 signal transduction, 178, 438, 440
 defective, 186
 skeletal muscle, 445
 sources, 433, 434–5, 436
 Stat proteins, 438
 structure, 432–3, 437–8
 T cells, 442–3, 448, 1214–15, *Plate*
53.4
 TCRs, 440
 transgenic animals, 446–7
in vivo effects, 445–6
- IL-15R α , 173, 436, 437–8
- IL-16, 465–71
 bioactivity, 466, 468–9
 birds, 71
- CD4 interaction, 468
 cell sources, 467
 function, 466–7, 471
 gene
 post-translational modification,
 466, *Plate 19.2*
 structure, 465–6, *Plate 19.1*
- HIV infection, 469–70
 inflammation, 470
 neuronal (NIL-16), 471
 properties, 471
 sequence, 466–7
 signaling, 468
 structure, 466–7
 synthesis, 465–6
 T cells, 466, 467, 468–9
 TCR, 469
- IL-16R α and β chains, 655
- IL-17, 412, 475–97
 airway diseases, 495–6
 autoimmune disorders, 491–5
 biologic activities, 486, 487, 488–9
 cancer, 490–1
 cartilage effect, 493
 cytokine induction, 486, 487–8
 fibroblasts, 488–9
 function, 478
 gastric disorders, 495
 gene, 476
 hematopoiesis, 488–9
 human, 477, 478–9
 IL-8 stimulation, 488, 495
 IL-17B–F, 482–6
 immunopathologic conditions,
 489–97
 inflammatory skin disorders,
 496–7
 MAP kinases, 481
 mouse, 476–7
 NF- κ B, 479, 481
 nickel dermatitis, 497
 rheumatoid arthritis, 483–4, 491–4
 signaling, 479, 481–2
 structure, 478
 synergy with other cytokines, 486,
 488
 T cells, 478
 $\alpha\beta$ T cells, 477
 TNF- α synergy, 486, 488, 492
 transplantation, 489–90
- IL-17 receptor, 486
 birds, 71
 cloning, 479
 sequence, 479, 480
 signaling, 479, 481–2
- IL-17B, 482
- IL-17B receptor, 482
- IL-17C, 482
- IL-17E, 483
- IL-17F, 483–6
 sequence, 484, 485
 structure, 484
- IL-18, 233, 644, 645–6, 709–24, 735–6
 antiangiogenesis, 721–2, 1287
 antitumor activity, 721–2
 asthma, 1318, 1323–4
 bioassay, 1381
 biologic activity, 710
 birds, 70–1
 bone, 713
 cancer
 antitumor activity, 721–2
 gene therapy, 1342
 tumor growth promotion, 722
 cartilage, 713
 cellular expression, 712–13
 CNS, 713
 cytokine stimulation, 13
 cytolytic activity effect, 718
 deficiency, 644
 diagnostic use, 724
 Fas/Fas ligand signaling, 719, 722
 Fas ligand expression, 719
 gastrointestinal tract, 713
 gene, 710–11
 mapping, 710
 regulatory regions, 710–11
 Stat proteins, 711
 hormonal regulation, 711
 host defense, 720
 human, 71
 human disease states, 723–4
 IFN- γ induction, 570, 717
 IL-10 synergy, 717
 IL-12 synergy, 717, 723
 IL-13 production
 stimulation, 413
 suppression, 720
 infection, 720–1
 inflammatory response, 722, 723
 knockout mouse phenotypes,
 719–20
 microvesicle rapid release, 712
 pathological role, 722–4
 physiological role, 719–24
 processing, 711–12
 receptor binding, 655
 receptor-mediated release, 712
 skin, 712–13
 T cells, 712
 T_{H2} cytokine induction, 718
 TLR-like signals, 815
 transcriptional regulation, 648–9
 tumor growth promotion, 722

- viral infection, 720–1
in vitro activity, 717–19
- IL-18 binding protein (IL-18BP), 653, 657, 715–16, 736
- IL-18 receptor, 8, 9, 714–15
 composition, 714
 deficiency, 644
 expression, 714–15
 homology, 714
 IRAKs, 659–60
 localization, 714
 NK cells, 717
 regulation, 715
 signal transduction, 655, 716–17
 T cells, 715, 717
- IL-19, 627, 628–31
 expression, 630
 gene, 628, 630
- IL-20, 627–8, 629, 630, 631–2
 biologic functions, 631–2
 clinical relevance, 632
 protein, 631
 skin, 632
- IL-20 receptor, 631, 636
- IL-21, 431–2, 453–6
 NK cells, 456
 protein, 453
- IL-21 receptor, 453–4
 birds, 71
 genomic structure, 455
 signaling, 454–5
- IL-22, 627–8, 629, 630, 632–4
 binding protein, 634
 biologic effects, 633
 gene, 632–3
- IL-22 receptor, 633, 634, 636
 birds, 71
 signal transduction, 633, 634
- IL-23, 383, 384–5, 387
 biologic functions, 393–4
 IL-12R interaction, 390
 T_{H1} deficiency, 391
- IL-24, 627–8, 629, 630, 634–5
- IL-25, 13, 412, 483
- IL-26, 627–8, 629, 630, 635–6
- IL-27, 385, 388
 IL-12R interaction, 390–1
 IL-28A, 551
 IL-28B, 551
 IL-29, 551
- IL-TIF *see* IL-22
- IL1RN gene, 670–2
 allelic polymorphisms, 684–6
 disease association, 685–6
- IL10-1082 SNP, 23–4
- immune response, 57
 Flt3, 1001–2
- IL-7, 331
 lymphotoxin, 829–30, 831–2
 NF- κ B, 814
 RANKL, 875
 VEGF, 1026–7
- immune stimulation, 1356–7
- immune system, 19, 20, 810–11, *Plate 33.1*
 33.1
 activin, 1161–8
 CD95/CD95L, 889–92
 CX3CL1, 1106
 genetic variation, 20
 IL-2, 170
 IL-2R, 184–6
 IL-3, 207–8
 IL-6, 282–3
 IL-7, 305–6, 321–2, 328–31
 IL-10, 605
 IL-11, 371
 IL-12R, 389–90
 IL-13, 416–19
 IL-15, 451–3
 IL-24, 635
 lymphotoxin, 831–2
 MIF, 1040–1
 prolactin effects, 131, 134
 RANKL, 875
 regulation, xxiii
- immunity, adaptive, 809–10, *Plate 33.1*
- immunity, innate, 809–10, *Plate 33.1*
 defense systems, 831–2
 IFN- γ , 581–2
 lymphotoxin, 831–2
- immunoassays, 1377, 1378, 1382–4
 sandwich-type, 1384
 two-site principle, 1382, *Plate 61.2*
- immunodeficiency
 IL-7, 327
see also HIV infection
- immunogenetics, 19
- immunoglobulin superfamily, 715
see also individual named Igs
- immunohistochemistry, 1386–7, *Plate 61.4*
- immunometric assay (IRMA), 1382
- immunomodulation
 IFN type I, 556
 rhIL-11, 375–8
- immunostaining, 1386–7, *Plate 61.4*
- immunotherapy
 cancer, 324, 328
 Flt3, 1003–4
 IL-2/IL-2R system, 186–7
 IL-7, 324, 328, 330
 IL-15, 451–3
- in situ* hybridization (ISH), 1387, 1388
- infection/infectious disease
 cancer association, 1214–15
 CD95L, 892
 CXC chemokines, 1065–6
 Flt3, 1001
 fungal, 946, 947
 G-CSF, 531, 532
 GM-CSF, 509, 511, 513
 IL-1Ra, 679, 687, 690–1
 induction, 677
 IL-1RI, 652–3
 IL-4 animal models, 246–7
 IL-7 immune response, 328–31
 IL-9, 354
 IL-12 therapy, 395–6
 IL-15, 441, 452–3
 IL-18, 720–1
 lymphotoxin, 832
 M-CSF, 946, 947
 MIF, 1040, *Plate 45.3*
 parasitic
 IL-9, 354
 IL-18, 720
 pneumonia, 496
 TLR signaling, 817
 TNF effect on susceptibility, 850–1
 TRAIL/Apo2L therapeutic use, 866
 vaccines, 509, 512
see also HIV infection;
 mycobacterial infection; viral infection
- inflammation
 activin, 1165, 1166–7
 clinical syndromes, 1167–8
 antisense inhibitors, 1360, 1361–2
 atherosclerosis, 681
 B cells, 292
 cancer association, 1214–15, 1221–2
 CC chemokines, 1087
 CSF-1, 942–3, 945
 CX3CL1, 1104
 gene therapy, 1343
 HMGB1, 916–18
 IL-1, 643
 IL-1 α , 652
 IL-1 β , 651, 652
 IL-1Ra, 678
 induction, 677
 IL-1RI, 652–3, 661
 IL-6, 292
 IL-10, 608–9
 IL-12, 392
 IL-13, 416–17, 418
 IL-15, 447–9
 IL-16, 470
 M-CSF, 946
 systemic, 376

- inflammation (*continued*)
 - TNF therapy, 853
 - vagus nerve stimulation, 853
- inflammatory bowel disease
 - activin, 1167–8
 - HGF, 791
 - IL-1Ra, 683
 - IL-10, 609
 - rhIL-11, 377–8
 - IL-15, 448–9
 - IL-16, 470
 - MIF, 1042
 - see also* Crohn's disease; ulcerative colitis
- inflammatory demyelinating polyneuropathy, 724
- inflammatory lung disease, 418
 - GM-CSF production, 510
- inflammatory proliferative disease, chronic, 292–3
- inflammatory response
 - angiogenesis, 1281
 - IL-8, 495
 - IL-10R, 612
 - IL-18, 722, 723
- infliximab, 852, 1197, 1198, 1199, 1201
- influenza
 - vaccine, 512
 - virus, 651
- inhibin, 1153, 1156
 - activin signaling antagonism, 1157
 - cancer, 1155, 1161
 - genes, 1154, 1155
- inhibin A, 1122, 1155
- inhibin B, 1155
- inhibin-binding protein, 1156, 1157
- insulin, 6
 - sensitivity, 285
- insulin-like growth factors, 103
 - see also* IGF-1
- insulin receptor substrates, 129
- integrins, 761
 - endostatin interaction, 1284
- interferon/IL-10 gene cluster, 61
- interferon-induced genes, 553–5
- interferon-inducible protein 10 (IP-10), 1286, 1287
- interferon stimulated gene factor 3 (ISGF3) *see* ISGF3 complex
- interferon stimulated response element *see* ISRE
- interferons, 3, 4
 - amphibians, 58
 - antiangiogenic activity, 1286
 - antiviral mechanisms, 1235–6
 - birds, 59–61
 - fish, 58, 60
 - hepatitis B, 1237–8
 - hepatitis C, 1238
 - host defense, 1235–7
 - phylogeny, 58–61
 - proteins, 1233–4
 - receptor chains, 61
 - reptiles, 58–9
 - signaling, 1234
 - viral antagonists, 1237–8
 - type I, 58–60, 61, 549–58
 - antiproliferative functions, 555–6
 - antiviral mechanisms, 553–4
 - apoptosis regulation, 556
 - CSF-1, 937
 - genes, 549–50
 - immunomodulation, 556
 - inducers, 552
 - NK cells, 556
 - receptors, 553
 - signal transduction, 553, *Plate* 23.2
 - Stat proteins, 554, *Plate* 23.2
 - structure, 552, *Plate* 23.1
 - subtypes, 549–50
 - T cells, 557
 - therapeutic applications, 557–9
 - type II, 60–1, 567
 - see also* named IFNs
- interleukins
 - antiangiogenesis, 1286–7
 - phylogeny, 61–71
 - terminology, xxv
 - see also* named ILs
- intestinal epithelial cell 6 (IEL-6), 367
- intestinal intraepithelial lymphocytes (iIEL), 320–1
- intracellular adhesion molecule(s) (ICAMs)
 - IFN- γ receptor, 575
 - IL-17 enhanced surface expression, 486, 495
- intracellular adhesion molecule 1 (ICAM-1), 243
 - IL-1, 643
 - inhibitor, 1355, 1358–9
- intracytoplasmic cytokine (ICC) assays, 1390
- invertebrates, 57
 - FGF, 74–5
 - IL-6, 66
 - TGF β , 73
 - TNF, 71
- IRAKs, 659–60
 - IL-1R signaling, 735
 - IL-18R, 659
 - IL-18R signaling, 716
- IRF-1 transcriptional factor, 579
 - induction, 12
 - inhibition, 131
- IRF-3 transcriptional factor, 552, 1235–6
- IRF-7 transcriptional factor, 552
- Irinotecan *see* CPT-11
- IRS-1, 236
- IRS-2, 236
 - IL-9, 357
 - IL-13 signaling, 411
- ISGF3 complex, 88, 554, *Plate* 23.2
- ISIS 2302, 1355, 1358–9, 1363
- ISIS 2503, 1359
- ISIS 3521, 1359
- ISIS 5132, 1359
- ISIS 104838, 1363
- ISRE, 554, *Plate* 23.2
- JAB, IL-2 signaling, 183
- Jab1, 1043
- JAK kinases, 10, 85–7
 - activation, 10, 234
 - G-CSF signaling, 525, 535
 - IFN- γ signaling, 573–7
 - IFN signaling, 1234, 1237
 - IL-2R signaling molecules, 177
 - IL-3, 212, 214
 - IL-4, 1316
 - IL-11 signaling, 371
- JAK1, 10, 85
 - activation, 86
 - G-CSFR signaling, 535
 - IL-2R signaling molecules, 177
 - IL-6, 289
 - IL-7, 312
 - IL-9 receptor, 356, 357
 - IL-10R signaling, 614
 - IL-13 signaling, 411
 - IL-15, 438
 - Stat6 activation, 235
- JAK2, 10, 85, 115
 - activation, 86, 126, 130
 - erythropoietin receptor, 154–5
 - G-CSFR signaling, 535
 - GM-CSF receptor signaling, 506
 - IL-2 signaling, 181
 - IL-2R signaling molecules, 177
 - IL-6, 289
 - IL-11, 372
 - IL-12 receptor, 389
 - IL-15, 438
 - Stat5 signaling, 127–8
 - Stat6 activation, 235
 - substrates, 126–7
 - tyrosine phosphorylation, 130

- JAK3, 10, 85, 86–7
 γ_c association, 186
 IL-2 signaling, 181, 182
 IL-2R signaling molecules, 177–8
 IL-4 signaling, 236
 IL-7, 312
 IL-9 receptor, 356
 IL-13 signaling, 412
 IL-15, 438
 immunotherapy target, 187
 tyrosine phosphorylation, 236
- JAK-STAT signal transduction pathway, 10, 11, 127–8, 235
 CSF-1, 936
 IFN- γ , 574–80
 through IL-6R, 289–91
- Janus kinases *see* JAK kinases
- Jehovah's Witnesses, 1267
- JNK kinases, 129, 213–14, 481
 activin, 1161
 CD95 signaling, 899
 IL-1, 660
 IL-17, 481
 TGF β -induced expression, 1136, 1137
 TGF β signaling, 1133, 1135
 TNF production, 840
- c-jun*, 11
 expression regulation by IL-2, 181–2
 IL-3, 215
 TGF β -induced expression, 1136
- jun activation-domain binding protein (Jab1), 1043
- Jun N-terminal kinase (JNK) *see* JNK kinases
- Kaposi's sarcoma
 antiangiogenesis, 1281
 CC chemokines, 1093
 CXC chemokines, 1066
 FGF2, 750, 765
 FGFs, 758, 759, 763, 764
 GM-CSF, 511
 IFN- α immunotherapy, 1225
 IFN type I, 557, 559
 IL-6, 292
see also human herpesvirus 8 (HHV8)
- Kaposi's sarcoma cells, 750
- keratinocyte growth factor (KGF), 322, 632
- keratinocytes
 activin, 1163
 apoptosis, 444, 445, 447
 epiregulin, 975
 IL-1 family, 647
 IL-1Ra, 677
 IL-4, 497
 IL-8, 1062
 IL-10, 607
 IL-15, 433, 434, 444–5, 447
 IL-17, 497
 IL-18, 712–13
 IL-20, 632
 MIF expression, 1038, 1042
- kidney
 erythropoietin, 151
 HGF in development, 789
 MIF, 1042
 prolactin receptors, 133
- kidney disease
 chronic renal failure, 157
 CX3CL1, 1104
 CXC chemokines, 1068
 EGF precursor, 962–3
 IgA nephropathy, 451
 IL-1Ra, 682, 689
 gene therapy, 695–6
 IL-18, 722
- KILLER, 863
- c-kit*, 991, 992
 down-regulation, 208–9
 structure, 992
- LAK cells
 IL-2, 172
 IL-2-induced, 325
 IL-4, 242
 IL-7 cancer therapy, 325–6
 IL-12, 392
 IL-15-induced, 450, 452
- latency-associated peptide (LAP), 1120, 1121, *Plate 49.1*
- latent TGF β -binding protein (LTBP), 1120
- lectins, mannose-binding, 991
- Leishmania* infection, IL-7, 329, 330
- lentiviruses, 1338
- leucine-rich repeats (LRRs), 814, 815, *Plate 33.4*
- leukemia
 B-cell, 1217–18
 chronic lymphocytic, 324
 FGF2, 765
 Flt3, 997–9
 G-CSF, 533, 534
 G-CSFR, 534
 constitutive signaling, 538
 GM-CSF, 511–12, 513, 1269
 HTLV-1, 1216–17
 IFN- α immunotherapy, 1225
 IFN type I, 557, 558, 559
 IL-1R, 662
 IL-1Ra, 683
 IL-2, 171, 1216–17
 IL-3, 216–17
 IL-7, 324
 IL-9, 350, 351, 353
 IL-10, 1217–18
 IL-15, 449, 1221–2, *Plate 53.4*
 IL-17, 491
 NF κ B, 1215
 prolactin, 135
 stem cell mobilization, 1270
- leukemia inhibitory factor (LIF), IL-17-induced, 488
- leukemia inhibitory factor (LIF) receptor, 1263
- leukemic cells, differentiation induction, 284
- leukemogenesis, 1222, *Plate 53.4*
- leukocyte functional antigen 1 (LFA-1), 243, 1270
- leukocytes
 anti-TNF α therapy, 1199
 CC chemokines, 1084, 1088
 CX3CL1, 1104, 1106
 CX3CR1, 1107–8
 function modulation, 3
- LIGHT, 825
- limb morphogenesis, 1182
- limitin, 550
- lipid metabolism, IL-15, 445
- lipopolysaccharide (LPS), 811
 activin release activation, 1167
 chemokine receptors, 1090
 HMGB1 release, 916–17
 IL-1 β -deficient mice, 651
 IL-1Ra in blood, 677
 IL-1RI, 653
 IL-18 induction, 711, 712
 interleukin stimulation, 242, 243
 macrophage activation, 367
 monocyte activation, 415
 sensor, 811–12
 signaling pathway, 812
 TLR4 activation, 818
- 5-lipoxygenase, 1060
- 15-lipoxygenase, 414–15
- liver
 CD95/CD95L, 892
 erythropoietin, 151
 injury and IL-18-deficient mice, 719
 prolactin receptor up-regulation, 125
- liver transplantation
 Flt3, 1002
 hepatitis C, 1250
 long signal peptide (LSP), 436, 437
see also IL-15

- lovastatin, 1094
- LT α , 825
 cancer, 1219
 expression, 827–8, 830
 lymph nodes, 829–30
 lymphoid tissue biogenesis, 828–9
 spleen, 829–30
 structure, 826–7, *Plate 34.3*
- LT β , 825
 expression, 827–8, 830
 lymph nodes, 829–30
 lymphoid tissue biogenesis, 828–9
 spleen, 829–30
 structure, 826–7
- LT β receptor, 828
 lymph nodes, 829–30
 signaling, 827, 832
 spleen, 829–30
- lung
 antigen presenting cells, 1324
 dendritic cells, 1324
 HGF in development, 789
 TGF α expression, 966
- lung cancer
 IL-3, 216
 IL-18, 722
 resistance, 851
- lung disease
 allergic, 417–18
 CXC chemokines, 1067–8
 IL-1Ra, 681, 689
 gene therapy, 696
 inflammatory, 418
 GM-CSF production, 510
- Lyme arthritis, 478
- Lyme disease, 494
- lymph nodes, lymphotoxin, 829–30
- lymphocyte-activating factor (LAF), xxiv, 4
- lymphocyte-derived chemotactic factor (LCF), xxiii
- lymphocytes, xxiii
 activation-induced cell death, 719
 activin, 1165
 homeostasis, 331–2, 442, 446
 IL-15 regulation of development, 439–41
 intrathymic positive selection, 314
 TGF β -mediated apoptosis, 1139–40
 traffic regulation by CC
 chemokines, 1091–2, *Plate 47.2*
see also B cells; CD4⁺ T cells; CD8⁺ T cells; cytotoxic T cells (CTL); T cells; T_{H1} cells; T_{H2} cells
- lymphoid cells, IL-3, 204
- lymphoid follicle formation, 831
- lymphoid microarchitecture
 formation, 830–1
- lymphoid tissue biogenesis, 828–9
- lymphokine-activated killer cells *see* LAK cells
- lymphokines, xxiii, 20
 discovery, xxiii
 nomenclature, 5
 research, 3, 4
- lymphoma, 449
 B cell, 1217–18
 cutaneous T-cell, 323, 449
 G3139, 1359
 IFN- α immunotherapy, 1225
 IFN type I, 557, 558
 IL-1Ra, 683
 IL-2, 171
 IL-7Ra, 324
 IL-9, 350, 351
 IL-10, 1217–18
 IL-13, 419
 IL-15, 449, 1222, *Plate 53.4*
 IL-16, 469
 NF κ B, 1215
 prolactin, 135
 stem cell factor, 1014
 T-cell, 323–4
- lymphopoiesis, IL-7 mediated, 305
- lymphoproliferative disease, CD95, 889, 890
- lymphotoxin (LT), xxiv, 825–32, *Plate 34.1*
 B cells, 830
 cancer, 1219
 expression regulation, 827–8
 functions, 828–32
 immune response, 829–30, 831–2
 immune system, 831–2
 infection, 832
 lymph nodes, 829–30
 lymphoid follicle formation, 831
 lymphoid microarchitecture
 formation, 830–1
 peripheral lymphoid tissue
 biogenesis, 828–9
 signal transduction, 827, 829–31, *Plate 34.4*
 spleen, 829–30
 T cells, 830
 tissue distribution, 827–8
 TNFR, 825, 826–7, *Plate 34.1*
see also LT α ; LT β
- Lyn expression, 155, 537
- M-Ras, 357
- macrophage-activating factor (MAF), xxiv
- birds, 60
 IFN- γ , 581
- macrophage colony-stimulating factor (M-CSF), xxiii, 927–47, 1263
 cancer, 947
 cells, 945–6
 cell surface, 928
 cellular sources, 929
 clinical trials, 947
 gene
 regulation, 928–9
 structure, 928
 HIV infection, 946
 IL-4, 242
 IL-6 synergy, 283
 infection, 946, 947
 inflammation, 946
 microglia, 945
 osteoclasts, 944–5
 protein structure, 929
 soluble, 928
- macrophage colony-stimulating factor (M-CSF) receptor, 7
- macrophage-derived chemokine *see* CCL22
- macrophage inflammatory protein 1 (MIP-1), 1366
- macrophage inflammatory protein 2 (MIP-2), 1362–3
- macrophage inflammatory protein 3 α (MIP-3 α), 492
- macrophage inflammatory protein 3 β (MIP-3 β), 1306
- macrophage inflammatory proteins, 1084
- macrophage migration inhibitory factors (MIF), xxiv, 4, 1037–44, 1045
 activity, 1038–9, 1042–3
 ARDS, 1041–2
 asthma, 1041
 cancer, 1043, 1215–16, *Plate 45.4*
 cytokine expression, 1039–43
 disease states, 1039–43
 gene structure, 1038, *Plate 45.1*
 host response, 1040
 immune system, 1040–1
 infection, 1040, *Plate 45.3*
 p53 inhibition, 1043
 PAG interaction, 1043–4
 pathologic process association, 1045
 properties, 1045
 protein
 preformed stores, 1038–9
 production, 1038
 structure, 1038–9, *Plate 45.2*